<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - PAROXETINE- paroxetine hydrochloride anhydrous
tablet, film coated</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">PAROXETINE- paroxetine
hydrochloride anhydrous tablet, film coated<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APAROXETINE%2D%20Paroxetine%20Hydrochloride%20Anhydrous%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D08320ea3%2D8f93%2D6f04%2D5d1c%2Df69af3eb5a81%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=10mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=10mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
src=
"image.cfm?type=img&amp;name=10mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=20mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=20mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
src=
"image.cfm?type=img&amp;name=20mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
<h4 class="more closed">VIEW MORE</h4>
<div class="show-more">
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=30mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="2"><img id="zoom_3" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=30mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
src=
"image.cfm?type=img&amp;name=30mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=40mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="3"><img id="zoom_4" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=40mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
src=
"image.cfm?type=img&amp;name=40mg-30s-btl.jpg&amp;setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a class="tip" rel="tooltip" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects."
href="#boxedwarning">Boxed Warnings</a></li>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22PAROXETINE%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=PAROXETINE"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=PAROXETINE"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=PAROXETINE[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=PAROXETINE/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=PAROXETINE/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=PAROXETINE/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=PAROXETINE[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00364&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">60505-0083-0, 60505-0083-1, 60505-0083-2,
60505-0083-4, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>60505-0083-5,
60505-0083-9, 60505-0084-1, 60505-0084-2, 60505-0084-4,
60505-0084-5, 60505-0084-9, 60505-0097-1, 60505-0097-2,
60505-0097-4, 60505-0097-5, 60505-0097-7, 60505-0097-9,
60505-0101-1, 60505-0101-2, 60505-0101-4, 60505-0101-5,
60505-0101-7, 60505-0101-9</span></span></div>
</li>
<li><strong>Packager:</strong> Apotex Corp.</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">Abbreviated New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated September 1, 2014</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;type=pdf&amp;name=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;type=zip&amp;name=PAROXETINE"
target="_blank">XML</a></li>
<li class="medguide">Medication Guide: <a href=
"/dailymed/medguide.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
target="_blank">HTML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip"
rel="tooltip" href="#" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What
is this?)</a>
<div class="Warning toggle-content open"><a name=
"_8159213C-7EE2-2385-46F4-473276BA8961" id=
"_8159213C-7EE2-2385-46F4-473276BA8961"></a> <a name="section-1"
id="section-1"></a>
<h1>Suicidality and Antidepressant Drugs</h1>
<p class="First"><span class="Bold">Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior
(suicidality) in children, adolescents, and young adults in
short-term studies of major depressive disorder (MDD) and other
psychiatric disorders. Anyone considering the use of paroxetine
tablets, USP or any other antidepressant in a child, adolescent, or
young adult must balance this risk with the clinical need.
Short-term studies did not show an increase in the risk of
suicidality with antidepressants compared to placebo in adults
beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and
certain other psychiatric disorders are themselves associated with
increases in the risk of suicide. Patients of all ages who are
started on antidepressant therapy should be monitored appropriately
and observed closely for clinical worsening, suicidality, or
unusual changes in behavior. Families and caregivers should be
advised of the need for close observation and communication with
the prescriber. Paroxetine tablets, USP are not approved for use in
pediatric patients. (See <a href=
"#_7E089633-A458-6945-7A27-A428B2E04B8E">WARNINGS,</a><a href=
"#_7E089633-A458-6945-7A27-A428B2E04B8E">Clinical Worsening and
Suicide Risk</a>, <a href=
"#_259A88A0-AC95-16B2-8216-4981588ECC62">PRECAUTIONS,</a><a href=
"#_259A88A0-AC95-16B2-8216-4981588ECC62">Information for
Patients,</a> and <a href=
"#_EF939498-0657-131F-4224-2C5AFE6FE462">PRECAUTIONS,</a><a href=
"#_EF939498-0657-131F-4224-2C5AFE6FE462">Pediatric
Use</a>.)</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="_A5DD15B4-C6EF-14A4-B63E-B29BA69BD358" id=
"_A5DD15B4-C6EF-14A4-B63E-B29BA69BD358"></a> <a name="section-1"
id="section-1"></a>
<p class="First">Paroxetine hydrochloride is an orally administered
psychotropic drug. It is the hydrochloride salt of a
phenylpiperidine compound identified chemically as (-)-<span class=
"Italics">trans</span>-4<span class=
"Italics">R</span>-(4'-fluorophenyl)-3<span class=
"Italics">S</span>-[(3',4'-methylenedioxyphenoxy) methyl]
piperidine hydrochloride anhydrous and has the empirical formula of
C<span class="Sub">19</span>H<span class=
"Sub">20</span>FNO<span class="Sub">3</span>•HCl. The molecular
weight is 365.8 (anhydrous) (329.4 as free base). The structural
formula of paroxetine hydrochloride is:</p>
<div class="Figure"><img src=
"image.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;name=paroxetine-01.jpg"
alt="structure">
<p class="MultiMediaCaption"></p>
</div>
<p>Paroxetine hydrochloride is an odorless, off-white powder,
having a melting point range of 116° to 120°C and a solubility of
5.4 mg/mL in water.</p>
<p>Each film-coated tablet, for oral administration, contains
paroxetine hydrochloride equivalent to paroxetine as follows: 10
mg; 20 mg; 30 mg; 40 mg. Inactive ingredients consist of anhydrous
lactose, hydroxypropyl cellulose, hypromellose, magnesium stearate,
polyethylene glycol, sodium starch glycolate and titanium dioxide.
Paroxetine tablets comply with USP Related Impurities Test 1.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="_789222FE-AEEA-626B-45EB-42B78AA26763" id=
"_789222FE-AEEA-626B-45EB-42B78AA26763"></a> <a name="section-2"
id="section-2"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="43681-6"><a name=
"_64355820-ED0E-7BD9-715A-E5195C8326C1" id=
"_64355820-ED0E-7BD9-715A-E5195C8326C1"></a> <a name="section-2.1"
id="section-2.1"></a>
<h2>Pharmacodynamics</h2>
<p class="First">The efficacy of paroxetine in the treatment of
major depressive disorder, social anxiety disorder, obsessive
compulsive disorder (OCD), panic disorder (PD), generalized anxiety
disorder (GAD) is presumed to be linked to potentiation of
serotonergic activity in the central nervous system resulting from
inhibition of neuronal reuptake of serotonin (5-hydroxy-tryptamine,
5-HT). Studies at clinically relevant doses in humans have
demonstrated that paroxetine blocks the uptake of serotonin into
human platelets. <span class="Italics">In vitro</span> studies in
animals also suggest that paroxetine is a potent and highly
selective inhibitor of neuronal serotonin reuptake and has only
very weak effects on norepinephrine and dopamine neuronal reuptake.
<span class="Italics">In vitro</span> radioligand binding studies
indicate that paroxetine has little affinity for muscarinic,
alpha<span class="Sub">1</span>-, alpha<span class="Sub">2</span>-,
beta-adrenergic- dopamine (D<span class="Sub">2</span>)-,
5-HT<span class="Sub">1</span>-, 5-HT<span class="Sub">2</span>-,
and histamine (H<span class="Sub">1</span>)-receptors; antagonism
of muscarinic, histaminergic, and alpha<span class=
"Sub">1</span>-adrenergic receptors has been associated with
various anticholinergic, sedative, and cardiovascular effects for
other psychotropic drugs.</p>
<p>Because the relative potencies of paroxetine’s major metabolites
are at most 1/50 of the parent compound, they are essentially
inactive.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"_D16354FE-4323-DC3D-2A75-DE54A917325F" id=
"_D16354FE-4323-DC3D-2A75-DE54A917325F"></a> <a name="section-2.2"
id="section-2.2"></a>
<h2>Pharmacokinetics</h2>
<p class="First">Paroxetine hydrochloride is completely absorbed
after oral dosing of a solution of the hydrochloride salt. The mean
elimination half-life is approximately 21 hours (CV 32%) after oral
dosing of 30 mg tablets of paroxetine daily for 30 days. Paroxetine
is extensively metabolized and the metabolites are considered to be
inactive. Nonlinearity in pharmacokinetics is observed with
increasing doses. Paroxetine metabolism is mediated in part by
CYP2D6, and the metabolites are primarily excreted in the urine and
to some extent in the feces. Pharmacokinetic behavior of paroxetine
has not been evaluated in subjects who are deficient in CYP2D6
(poor metabolizers).</p>
<p>In a meta-analysis of paroxetine from 4 studies done in healthy
volunteers following multiple dosing of 20 mg/day to 40 mg/day,
males did not exhibit a significantly lower C<span class=
"Sub">max</span> or AUC than females.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9758FCA6-50F8-2A5F-BAEC-902969C868CC" id=
"_9758FCA6-50F8-2A5F-BAEC-902969C868CC"></a> <a name=
"section-2.2.1" id="section-2.2.1"></a>
<h3><span class="Bold Italics">Absorption and
Distribution</span></h3>
<p class="First">Paroxetine is equally bioavailable from the oral
suspension and tablet.</p>
<p>Paroxetine hydrochloride is completely absorbed after oral
dosing of a solution of the hydrochloride salt. In a study in which
normal male subjects (n = 15) received 30 mg tablets daily for 30
days, steady-state paroxetine concentrations were achieved by
approximately 10 days for most subjects, although it may take
substantially longer in an occasional patient. At steady state,
mean values of C<span class="Sub">max</span>, T<span class=
"Sub">max</span>, C<span class="Sub">min</span>, and T½ were 61.7
ng/mL (CV 45%), 5.2 hr. (CV 10%), 30.7 ng/mL (CV 67%), and 21.0
hours (CV 32%), respectively. The steady-state C<span class=
"Sub">max</span> and C<span class="Sub">min</span> values were
about 6 and 14 times what would be predicted from single-dose
studies. Steady-state drug exposure based on AUC<span class=
"Sub">0-24</span> was about 8 times greater than would have been
predicted from single-dose data in these subjects. The excess
accumulation is a consequence of the fact that 1 of the enzymes
that metabolizes paroxetine is readily saturable.</p>
<p>The effects of food on the bioavailability of paroxetine were
studied in subjects administered a single dose with and without
food. AUC was only slightly increased (6%) when drug was
administered with food but the C<span class="Sub">max</span> was
29% greater, while the time to reach peak plasma concentration
decreased from 6.4 hours post-dosing to 4.9 hours.</p>
<p>Paroxetine distributes throughout the body, including the CNS,
with only 1% remaining in the plasma.</p>
<p>Approximately 95% and 93% of paroxetine is bound to plasma
protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical
conditions, paroxetine concentrations would normally be less than
400 ng/mL. Paroxetine does not alter the <span class="Italics">in
vitro</span> protein binding of phenytoin or warfarin.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_B2972128-368A-805E-C827-3C87836A15A1" id=
"_B2972128-368A-805E-C827-3C87836A15A1"></a> <a name=
"section-2.2.2" id="section-2.2.2"></a>
<h3><span class="Bold Italics">Metabolism and Excretion</span></h3>
<p class="First">The mean elimination half-life is approximately 21
hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days
of Paroxetine hydrochloride. In steady-state dose proportionality
studies involving elderly and nonelderly patients, at doses of 20
mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the
nonelderly, some nonlinearity was observed in both populations,
again reflecting a saturable metabolic pathway. In comparison to
C<span class="Sub">min</span> values after 20 mg daily, values
after 40 mg daily were only about 2 to 3 times greater than
doubled.</p>
<p>Paroxetine is extensively metabolized after oral administration.
The principal metabolites are polar and conjugated products of
oxidation and methylation, which are readily cleared. Conjugates
with glucuronic acid and sulfate predominate, and major metabolites
have been isolated and identified. Data indicate that the
metabolites have no more than 1/50 the potency of the parent
compound at inhibiting serotonin uptake. The metabolism of
paroxetine is accomplished in part by CYP2D6. Saturation of this
enzyme at clinical doses appears to account for the nonlinearity of
paroxetine kinetics with increasing dose and increasing duration of
treatment. The role of this enzyme in paroxetine metabolism also
suggests potential drug-drug interactions (see <span class=
"Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS, Drugs
Metabolized by CYP2D6</a></span>).</p>
<p>Approximately 64% of a 30-mg oral solution dose of paroxetine
was excreted in the urine with 2% as the parent compound and 62% as
metabolites over a 10-day post-dosing period. About 36% was
excreted in the feces (probably via the bile), mostly as
metabolites and less than 1% as the parent compound over the 10-day
post-dosing period.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_FF0E24D9-057B-03DD-B88E-C9B5ED7B7410" id=
"_FF0E24D9-057B-03DD-B88E-C9B5ED7B7410"></a> <a name="section-2.3"
id="section-2.3"></a>
<h2>Other Clinical Pharmacology Information</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_11655E02-2318-6E1E-762E-71F33A9191CE" id=
"_11655E02-2318-6E1E-762E-71F33A9191CE"></a> <a name=
"section-2.3.1" id="section-2.3.1"></a>
<h3><span class="Bold Italics">Specific Populations</span></h3>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_07E7720C-1225-2E61-5BF8-9C9E221EE64B" id=
"_07E7720C-1225-2E61-5BF8-9C9E221EE64B"></a> <a name=
"section-2.3.1.1" id="section-2.3.1.1"></a>
<h4>Renal and Liver Disease</h4>
<p class="First">Increased plasma concentrations of paroxetine
occur in subjects with renal and hepatic impairment. The mean
plasma concentrations in patients with creatinine clearance below
30 mL/min. were approximately 4 times greater than seen in normal
volunteers. Patients with creatinine clearance of 30 to 60 mL/min.
and patients with hepatic functional impairment had about a 2-fold
increase in plasma concentrations (AUC, C<span class=
"Sub">max</span>).</p>
<p>The initial dosage should therefore be reduced in patients with
severe renal or hepatic impairment, and upward titration, if
necessary, should be at increased intervals (see <span class=
"Bold"><a href="#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_2B7D323C-E5B9-0494-7C89-E2A00C462CE0" id=
"_2B7D323C-E5B9-0494-7C89-E2A00C462CE0"></a> <a name=
"section-2.3.1.2" id="section-2.3.1.2"></a>
<h4>Elderly Patients</h4>
<p class="First">In a multiple-dose study in the elderly at daily
paroxetine doses of 20, 30, and 40 mg, C<span class=
"Sub">min</span> concentrations were about 70% to 80% greater than
the respective C<span class="Sub">min</span> concentrations in
nonelderly subjects. Therefore the initial dosage in the elderly
should be reduced (see <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D3D73330-73E9-5F2F-F821-8EEC55D0E7F2" id=
"_D3D73330-73E9-5F2F-F821-8EEC55D0E7F2"></a> <a name=
"section-2.3.1.3" id="section-2.3.1.3"></a>
<h4><span class="Bold Italics">Drug-Drug Interactions</span></h4>
<p class="First"><span class="Italics">In vitro</span> drug
interaction studies reveal that paroxetine inhibits CYP2D6.
Clinical drug interaction studies have been performed with
substrates of CYP2D6 and show that paroxetine can inhibit the
metabolism of drugs metabolized by CYP2D6 including desipramine,
risperidone, and atomoxetine (see <span class="Bold"><a href=
"#_ABAA2F32-1552-4C00-CA79-B42E5E3A2AD2">PRECAUTIONS, Drug
Interactions</a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_B643AA0D-BCAD-CB26-AC86-6BE333846CA0" id=
"_B643AA0D-BCAD-CB26-AC86-6BE333846CA0"></a> <a name="section-2.4"
id="section-2.4"></a>
<h2>Clinical Trials</h2>
<p class="First"></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_FBE79512-ADFD-DFCD-D316-A1CCA50B2DB5" id=
"_FBE79512-ADFD-DFCD-D316-A1CCA50B2DB5"></a> <a name="section-2.5"
id="section-2.5"></a>
<h2><span class="Bold Italics">Major Depressive
Disorder</span></h2>
<p class="First">The efficacy of paroxetine as a treatment for
major depressive disorder has been established in 6
placebo-controlled studies of patients with major depressive
disorder (aged 18 to 73). In these studies, paroxetine was shown to
be significantly more effective than placebo in treating major
depressive disorder by at least 2 of the following measures:
Hamilton Depression Rating Scale (HDRS), the Hamilton depressed
mood item, and the Clinical Global Impression (CGI)-Severity of
Illness. Paroxetine was significantly better than placebo in
improvement of the HDRS sub-factor scores, including the depressed
mood item, sleep disturbance factor, and anxiety factor.</p>
<p>A study of outpatients with major depressive disorder who had
responded to paroxetine (HDRS total score &lt;8) during an initial
8-week open-treatment phase and were then randomized to
continuation on paroxetine or placebo for 1 year demonstrated a
significantly lower relapse rate for patients taking paroxetine
(15%) compared to those on placebo (39%). Effectiveness was similar
for male and female patients.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_E02CD032-B999-BF16-35C8-DC72C803CCA6" id=
"_E02CD032-B999-BF16-35C8-DC72C803CCA6"></a> <a name="section-2.6"
id="section-2.6"></a>
<h2><span class="Bold Italics">Obsessive Compulsive
Disorder</span></h2>
<p class="First">The effectiveness of paroxetine in the treatment
of obsessive compulsive disorder (OCD) was demonstrated in two
12-week multicenter placebo-controlled studies of adult outpatients
(Studies 1 and 2). Patients in all studies had moderate to severe
OCD (DSM-IIIR) with mean baseline ratings on the Yale Brown
Obsessive Compulsive Scale (YBOCS) total score ranging from 23 to
26. Study 1, a dose-range finding study where patients were treated
with fixed doses of 20, 40, or 60 mg of paroxetine/day demonstrated
that daily doses of paroxetine 40 and 60 mg are effective in the
treatment of OCD. Patients receiving doses of 40 and 60 mg
paroxetine experienced a mean reduction of approximately 6 and 7
points, respectively, on the YBOCS total score which was
significantly greater than the approximate 4-point reduction at 20
mg and a 3-point reduction in the placebo-treated patients. Study 2
was a flexible-dose study comparing paroxetine (20 to 60 mg daily)
with clomipramine (25 to 250 mg daily). In this study, patients
receiving paroxetine experienced a mean reduction of approximately
7 points on the YBOCS total score, which was significantly greater
than the mean reduction of approximately 4 points in
placebo-treated patients.</p>
<p>The following table provides the outcome classification by
treatment group on Global Improvement items of the Clinical Global
Impression (CGI) scale for Study 1.</p>
<div class="scrollingtable">
<table frame="box" width="75%">
<tbody class="Headless">
<tr class="First">
<td align="center" colspan="5"><span class="Bold">Outcome
Classification (%) on CGI-Global Improvement Item <span class=
"Bold">for Completers in Study 1</span></span></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2"><span class="Bold">Outcome
Classification</span></td>
<td align="center" colspan="1" rowspan="2"><span class=
"Bold">Placebo</span><span class="Bold">(n=74)</span></td>
<td align="center" colspan="1"><span class="Bold">Paroxetine 20
mg</span></td>
<td align="center" colspan="1" rowspan="1"><span class=
"Bold">Paroxetine 40 mg</span></td>
<td align="center" colspan="1"><span class="Bold">Paroxetine 60
mg</span></td>
</tr>
<tr>
<td align="center" colspan="1"><span class=
"Bold">(n=75)</span></td>
<td align="center" colspan="1"><span class=
"Bold">(n=66)</span></td>
<td align="center" colspan="1"><span class=
"Bold">(n=66)</span></td>
</tr>
<tr>
<td align="left" colspan="1">Worse</td>
<td align="center" colspan="1">14%</td>
<td align="center" colspan="1">7%</td>
<td align="center" colspan="1">7%</td>
<td align="center" colspan="1">3%</td>
</tr>
<tr>
<td align="left" colspan="1">No Change</td>
<td align="center" colspan="1">44%</td>
<td align="center" colspan="1">35%</td>
<td align="center" colspan="1">22%</td>
<td align="center" colspan="1">19%</td>
</tr>
<tr>
<td align="left" colspan="1">Minimally Improved</td>
<td align="center" colspan="1">24%</td>
<td align="center" colspan="1">33%</td>
<td align="center" colspan="1">29%</td>
<td align="center" colspan="1">34%</td>
</tr>
<tr>
<td align="left" colspan="1">Much Improved</td>
<td align="center" colspan="1">11%</td>
<td align="center" colspan="1">18%</td>
<td align="center" colspan="1">22%</td>
<td align="center" colspan="1">24%</td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Very Much Improved</td>
<td align="center" colspan="1">7%</td>
<td align="center" colspan="1">7%</td>
<td align="center" colspan="1">20%</td>
<td align="center" colspan="1">20%</td>
</tr>
</tbody>
</table>
</div>
<p>Subgroup analyses did not indicate that there were any
differences in treatment outcomes as a function of age or
gender.</p>
<p>The long-term maintenance effects of paroxetine in OCD were
demonstrated in a long-term extension to Study 1. Patients who were
responders on paroxetine during the 3-month double-blind phase and
a 6-month extension on open-label paroxetine (20 to 60 mg/day) were
randomized to either paroxetine or placebo in a 6-month
double-blind relapse prevention phase. Patients randomized to
paroxetine were significantly less likely to relapse than
comparably treated patients who were randomized to placebo.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_DB015B30-28F4-1557-2C54-299180143668" id=
"_DB015B30-28F4-1557-2C54-299180143668"></a> <a name="section-2.7"
id="section-2.7"></a>
<h2><span class="Bold Italics">Panic Disorder</span></h2>
<p class="First">The effectiveness of paroxetine in the treatment
of panic disorder was demonstrated in three 10- to 12-week
multicenter, placebo-controlled studies of adult outpatients
(Studies 1 to 3). Patients in all studies had panic disorder
(DSM-IIIR), with or without agoraphobia. In these studies,
paroxetine was shown to be significantly more effective than
placebo in treating panic disorder by at least 2 out of 3 measures
of panic attack frequency and on the Clinical Global Impression
Severity of Illness score.</p>
<p>Study 1 was a 10-week dose-range finding study; patients were
treated with fixed paroxetine doses of 10, 20, or 40 mg/day or
placebo. A significant difference from placebo was observed only
for the 40 mg/day group. At endpoint, 76% of patients receiving
paroxetine 40 mg/day were free of panic attacks, compared to 44% of
placebo-treated patients.</p>
<p>Study 2 was a 12-week flexible-dose study comparing paroxetine
(10 to 60 mg daily) and placebo. At endpoint, 51% of paroxetine
patients were free of panic attacks compared to 32% of
placebo-treated patients.</p>
<p>Study 3 was a 12-week flexible-dose study comparing paroxetine
(10 to 60 mg daily) to placebo in patients concurrently receiving
standardized cognitive behavioral therapy. At endpoint, 33% of the
paroxetine-treated patients showed a reduction to 0 or 1 panic
attacks compared to 14% of placebo patients.</p>
<p>In both Studies 2 and 3, the mean paroxetine dose for completers
at endpoint was approximately 40 mg/day of paroxetine.</p>
<p>Long-term maintenance effects of paroxetine in panic disorder
were demonstrated in an extension to Study 1. Patients who were
responders during the 10-week double-blind phase and during a
3-month double-blind extension phase were randomized to either
paroxetine (10, 20, or 40 mg/day) or placebo in a 3-month
double-blind relapse prevention phase. Patients randomized to
paroxetine were significantly less likely to relapse than
comparably treated patients who were randomized to placebo.</p>
<p>Subgroup analyses did not indicate that there were any
differences in treatment outcomes as a function of age or
gender.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_66EC87C3-B86C-1C92-852B-B17FC7761961" id=
"_66EC87C3-B86C-1C92-852B-B17FC7761961"></a> <a name="section-2.8"
id="section-2.8"></a>
<h2><span class="Bold Italics">Social Anxiety Disorder</span></h2>
<p class="First">The effectiveness of paroxetine in the treatment
of social anxiety disorder was demonstrated in three 12-week,
multicenter, placebo-controlled studies (Studies 1, 2, and 3) of
adult outpatients with social anxiety disorder (DSM-IV). In these
studies, the effectiveness of paroxetine compared to placebo was
evaluated on the basis of (1) the proportion of responders, as
defined by a Clinical Global Impression (CGI) Improvement score of
1 (very much improved) or 2 (much improved), and (2) change from
baseline in the Liebowitz Social Anxiety Scale (LSAS).</p>
<p>Studies 1 and 2 were flexible-dose studies comparing paroxetine
(20 to 50 mg daily) and placebo. Paroxetine demonstrated
statistically significant superiority over placebo on both the CGI
Improvement responder criterion and the Liebowitz Social Anxiety
Scale (LSAS). In Study 1, for patients who completed to week 12,
69% of paroxetine-treated patients compared to 29% of
placebo-treated patients were CGI Improvement responders. In Study
2, CGI Improvement responders were 77% and 42% for the paroxetine-
and placebo-treated patients, respectively.</p>
<p>Study 3 was a 12-week study comparing fixed paroxetine doses of
20, 40, or 60 mg/day with placebo. Paroxetine 20 mg was
demonstrated to be significantly superior to placebo on both the
LSAS Total Score and the CGI Improvement responder criterion; there
were trends for superiority over placebo for the 40 mg and 60
mg/day dose groups. There was no indication in this study of any
additional benefit for doses higher than 20 mg/day.</p>
<p>Subgroup analyses generally did not indicate differences in
treatment outcomes as a function of age, race, or gender.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_A2C3544D-1E36-B134-B7CF-E40BBB2685D3" id=
"_A2C3544D-1E36-B134-B7CF-E40BBB2685D3"></a> <a name="section-2.9"
id="section-2.9"></a>
<h2><span class="Bold Italics">Generalized Anxiety
Disorder</span></h2>
<p class="First">The effectiveness of paroxetine in the treatment
of Generalized Anxiety Disorder (GAD) was demonstrated in two
8-week, multicenter, placebo-controlled studies (Studies 1 and 2)
of adult outpatients with Generalized Anxiety Disorder
(DSM-IV).</p>
<p>Study 1 was an 8-week study comparing fixed paroxetine doses of
20 mg or 40 mg/day with placebo. Doses of 20 mg or 40 mg of
paroxetine were both demonstrated to be significantly superior to
placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total
score. There was not sufficient evidence in this study to suggest a
greater benefit for the 40 mg/day dose compared to the 20 mg/day
dose.</p>
<p>Study 2 was a flexible-dose study comparing paroxetine (20 mg to
50 mg daily) and placebo. Paroxetine demonstrated statistically
significant superiority over placebo on the Hamilton Rating Scale
for Anxiety (HAM-A) total score. A third study, also flexible-dose
comparing paroxetine (20 mg to 50 mg daily), did not demonstrate
statistically significant superiority of paroxetine over placebo on
the Hamilton Rating Scale for Anxiety (HAM-A) total score, the
primary outcome.</p>
<p>Subgroup analyses did not indicate differences in treatment
outcomes as a function of race or gender. There were insufficient
elderly patients to conduct subgroup analyses on the basis of
age.</p>
<p>In a longer-term trial, 566 patients meeting DSM-IV criteria for
Generalized Anxiety Disorder, who had responded during a
single-blind, 8-week acute treatment phase with 20 to 50 mg/day of
paroxetine, were randomized to continuation of paroxetine at their
same dose, or to placebo, for up to 24 weeks of observation for
relapse. Response during the single-blind phase was defined by
having a decrease of ≥2 points compared to baseline on the
CGI-Severity of Illness scale, to a score of ≤3. Relapse during the
double-blind phase was defined as an increase of ≥ 2 points
compared to baseline on the CGI-Severity of Illness scale to a
score of ≥ 4, or withdrawal due to lack of efficacy. Patients
receiving continued paroxetine experienced a significantly lower
relapse rate over the subsequent 24 weeks compared to those
receiving placebo.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="_BBDDC165-BCAB-D543-B1D0-83B67377679A" id=
"_BBDDC165-BCAB-D543-B1D0-83B67377679A"></a> <a name="section-3"
id="section-3"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_820FC91C-2251-C866-B3EB-F6E4887CC97F" id=
"_820FC91C-2251-C866-B3EB-F6E4887CC97F"></a> <a name="section-3.1"
id="section-3.1"></a>
<h2>Major Depressive Disorder</h2>
<p class="First">Paroxetine tablets, USP are indicated for the
treatment of major depressive disorder.</p>
<p>The efficacy of paroxetine in the treatment of a major
depressive episode was established in 6-week controlled trials of
outpatients whose diagnoses corresponded most closely to the
DSM-III category of major depressive disorder (see <span class=
"Bold"><a href="#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL
PHARMACOLOGY, Clinical Trials</a></span>). A major depressive
episode implies a prominent and relatively persistent depressed or
dysphoric mood that usually interferes with daily functioning
(nearly every day for at least 2 weeks); it should include at least
4 of the following 8 symptoms: Change in appetite, change in sleep,
psychomotor agitation or retardation, loss of interest in usual
activities or decrease in sexual drive, increased fatigue, feelings
of guilt or worthlessness, slowed thinking or impaired
concentration, and a suicide attempt or suicidal ideation.</p>
<p>The effects of paroxetine in hospitalized depressed patients
have not been adequately studied.</p>
<p>The efficacy of paroxetine in maintaining a response in major
depressive disorder for up to 1 year was demonstrated in a
placebo-controlled trial (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>). Nevertheless, the physician who elects
to use paroxetine for extended periods should periodically
re-evaluate the long-term usefulness of the drug for the individual
patient.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_C5CE5C6F-32AD-6EDE-E0B2-315F23287315" id=
"_C5CE5C6F-32AD-6EDE-E0B2-315F23287315"></a> <a name="section-3.2"
id="section-3.2"></a>
<h2>Obsessive Compulsive Disorder</h2>
<p class="First">Paroxetine tablets, USP are indicated for the
treatment of obsessions and compulsions in patients with obsessive
compulsive disorder (OCD) as defined in the DSM-IV. The obsessions
or compulsions cause marked distress, are time-consuming, or
significantly interfere with social or occupational
functioning.</p>
<p>The efficacy of paroxetine was established in two 12-week trials
with obsessive compulsive outpatients whose diagnoses corresponded
most closely to the DSM-IIIR category of obsessive compulsive
disorder (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>).</p>
<p>Obsessive compulsive disorder is characterized by recurrent and
persistent ideas, thoughts, impulses, or images (obsessions) that
are ego-dystonic and/or repetitive, purposeful, and intentional
behaviors (compulsions) that are recognized by the person as
excessive or unreasonable.</p>
<p>Long-term maintenance of efficacy was demonstrated in a 6-month
relapse prevention trial. In this trial, patients assigned to
paroxetine showed a lower relapse rate compared to patients on
placebo (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>). Nevertheless, the physician who elects
to use paroxetine for extended periods should periodically
re-evaluate the long-term usefulness of the drug for the individual
patient (see <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_C6026F26-415F-6197-38F8-E5DBB5B079FF" id=
"_C6026F26-415F-6197-38F8-E5DBB5B079FF"></a> <a name="section-3.3"
id="section-3.3"></a>
<h2>Panic Disorder</h2>
<p class="First">Paroxetine tablets, USP are indicated for the
treatment of panic disorder, with or without agoraphobia, as
defined in DSM-IV. Panic disorder is characterized by the
occurrence of unexpected panic attacks and associated concern about
having additional attacks, worry about the implications or
consequences of the attacks, and/or a significant change in
behavior related to the attacks.</p>
<p>The efficacy of paroxetine was established in three 10- to
12-week trials in panic disorder patients whose diagnoses
corresponded to the DSM-IIIR category of panic disorder (see
<span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>).</p>
<p>Panic disorder (DSM-IV) is characterized by recurrent unexpected
panic attacks, i.e., a discrete period of intense fear or
discomfort in which 4 (or more) of the following symptoms develop
abruptly and reach a peak within 10 minutes: (1) palpitations,
pounding heart, or accelerated heart rate; (2) sweating; (3)
trembling or shaking; (4) sensations of shortness of breath or
smothering; (5) feeling of choking; (6) chest pain or discomfort;
(7) nausea or abdominal distress; (8) feeling dizzy, unsteady,
lightheaded, or faint; (9) derealization (feelings of unreality) or
depersonalization (being detached from oneself); (10) fear of
losing control; (11) fear of dying; (12) paresthesias (numbness or
tingling sensations); (13) chills or hot flushes.</p>
<p>Long-term maintenance of efficacy was demonstrated in a 3-month
relapse prevention trial. In this trial, patients with panic
disorder assigned to paroxetine demonstrated a lower relapse rate
compared to patients on placebo (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>). Nevertheless, the physician who
prescribes paroxetine for extended periods should periodically
re-evaluate the long-term usefulness of the drug for the individual
patient (see <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_4524A95C-9B4D-C408-0386-FA84222B7E46" id=
"_4524A95C-9B4D-C408-0386-FA84222B7E46"></a> <a name="section-3.4"
id="section-3.4"></a>
<h2>Social Anxiety Disorder</h2>
<p class="First">Paroxetine tablets, USP are indicated for the
treatment of social anxiety disorder, also known as social phobia,
as defined in DSM-IV (300.23). Social anxiety disorder is
characterized by a marked and persistent fear of 1 or more social
or performance situations in which the person is exposed to
unfamiliar people or to possible scrutiny by others. Exposure to
the feared situation almost invariably provokes anxiety, which may
approach the intensity of a panic attack. The feared situations are
avoided or endured with intense anxiety or distress. The avoidance,
anxious anticipation, or distress in the feared situation(s)
interferes significantly with the person's normal routine,
occupational or academic functioning, or social activities or
relationships, or there is marked distress about having the
phobias. Lesser degrees of performance anxiety or shyness generally
do not require psychopharmacological treatment.</p>
<p>The efficacy of paroxetine was established in three 12-week
trials in adult patients with social anxiety disorder (DSM-IV).
Paroxetine has not been studied in children or adolescents with
social phobia (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>).</p>
<p>The effectiveness of paroxetine in long-term treatment of social
anxiety disorder, i.e., for more than 12 weeks, has not been
systematically evaluated in adequate and well-controlled trials.
Therefore, the physician who elects to prescribe paroxetine for
extended periods should periodically re-evaluate the long-term
usefulness of the drug for the individual patient (see <span class=
"Bold"><a href="#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D4730AFB-EDCC-4071-B51E-7A7C5E01CEC2" id=
"_D4730AFB-EDCC-4071-B51E-7A7C5E01CEC2"></a> <a name="section-3.5"
id="section-3.5"></a>
<h2>Generalized Anxiety Disorder</h2>
<p class="First">Paroxetine tablets, USP are indicated for the
treatment of Generalized Anxiety Disorder (GAD), as defined in
DSM-IV. Anxiety or tension associated with the stress of everyday
life usually does not require treatment with an anxiolytic.</p>
<p>The efficacy of paroxetine in the treatment of GAD was
established in two 8-week placebo-controlled trials in adults with
GAD. Paroxetine has not been studied in children or adolescents
with Generalized Anxiety Disorder (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>).</p>
<p>Generalized Anxiety Disorder (DSM-IV) is characterized by
excessive anxiety and worry (apprehensive expectation) that is
persistent for at least 6 months and which the person finds
difficult to control. It must be associated with at least 3 of the
following 6 symptoms: Restlessness or feeling keyed up or on edge,
being easily fatigued, difficulty concentrating or mind going
blank, irritability, muscle tension, sleep disturbance.</p>
<p>The efficacy of paroxetine in maintaining a response in patients
with Generalized Anxiety Disorder, who responded during an 8-week
acute treatment phase while taking paroxetine and were then
observed for relapse during a period of up to 24 weeks, was
demonstrated in a placebo-controlled trial (see <span class=
"Bold"><a href="#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL
PHARMACOLOGY, Clinical Trials</a></span>). Nevertheless, the
physician who elects to use paroxetine for extended periods should
periodically re-evaluate the long-term usefulness of the drug for
the individual patient (see <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="_49158A19-DB4A-CA1C-9F32-848D196EBDF7" id=
"_49158A19-DB4A-CA1C-9F32-848D196EBDF7"></a> <a name="section-4"
id="section-4"></a>
<p class="First">The use of MAOIs intended to treat psychiatric
disorders with paroxetine tablets or within 14 days of stopping
treatment with, paroxetine tablets is contraindicated because of an
increased risk of serotonin syndrome. The use of paroxetine within
14 days of stopping an MAOI intended to treat psychiatric disorders
is also contraindicated (see <span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span> and
<span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
<p>Starting paroxetine tablets in a patient who is being treated
with MAOIs such as linezolid or intravenous methylene blue is also
contraindicated because of an increased risk of serotonin syndrome
(see <span class="Bold"><span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span></span>
and <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span><span class="Bold"><span class=
"Bold">).</span></span></p>
<p>Concomitant use with thioridazine is contraindicated (see
<span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span> and
<span class="Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS</a></span>).</p>
<p>Concomitant use in patients taking pimozide is contraindicated
(see <span class="Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS</a></span>).</p>
<p>Paroxetine tablets are contraindicated in patients with a
hypersensitivity to paroxetine or any of the inactive ingredients
in paroxetine tablets.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">WARNINGS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34071-1"><a name="_43D3F4B6-1241-968E-D33D-EEB9737A9D17" id=
"_43D3F4B6-1241-968E-D33D-EEB9737A9D17"></a> <a name="section-5"
id="section-5"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_7E089633-A458-6945-7A27-A428B2E04B8E" id=
"_7E089633-A458-6945-7A27-A428B2E04B8E"></a> <a name="section-5.1"
id="section-5.1"></a>
<h2>Clinical Worsening and Suicide Risk</h2>
<p class="First">Patients with major depressive disorder (MDD),
both adult and pediatric, may experience worsening of their
depression and/or the emergence of suicidal ideation and behavior
(suicidality) or unusual changes in behavior, whether or not they
are taking antidepressant medications, and this risk may persist
until significant remission occurs. Suicide is a known risk of
depression and certain other psychiatric disorders, and these
disorders themselves are the strongest predictors of suicide. There
has been a long-standing concern, however, that antidepressants may
have a role in inducing worsening of depression and the emergence
of suicidality in certain patients during the early phases of
treatment. Pooled analyses of short-term placebo-controlled trials
of antidepressant drugs (SSRIs and others) showed that these drugs
increase the risk of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults (ages 18 to 24) with
major depressive disorder (MDD) and other psychiatric disorders.
Short-term studies did not show an increase in the risk of
suicidality with antidepressants compared to placebo in adults
beyond age 24; there was a reduction with antidepressants compared
to placebo in adults aged 65 and older.</p>
<p>The pooled analyses of placebo-controlled trials in children and
adolescents with MDD, obsessive compulsive disorder (OCD), or other
psychiatric disorders included a total of 24 short-term trials of 9
antidepressant drugs in over 4,400 patients. The pooled analyses of
placebo-controlled trials in adults with MDD or other psychiatric
disorders included a total of 295 short-term trials (median
duration of 2 months) of 11 antidepressant drugs in over 77,000
patients. There was considerable variation in risk of suicidality
among drugs, but a tendency toward an increase in the younger
patients for almost all drugs studied. There were differences in
absolute risk of suicidality across the different indications, with
the highest incidence in MDD. The risk differences (drug vs
placebo), however, were relatively stable within age strata and
across indications. These risk differences (drug-placebo difference
in the number of cases of suicidality per 1,000 patients treated)
are provided in Table 1.</p>
<div class="scrollingtable">
<table frame="border" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="center" colspan="2"><span class="Bold">Table
1</span></td>
</tr>
<tr>
<td align="center" colspan="1">Age Range</td>
<td align="center" colspan="1">Drug-Placebo Difference in
Number<br>
of Cases of Suicidality per 1,000<br>
Patients Treated</td>
</tr>
<tr>
<td align="center"></td>
<td align="center" rowspan="1">Increases Compared to Placebo</td>
</tr>
<tr>
<td align="center" colspan="1">&lt;18</td>
<td align="center" colspan="1">14 additional cases</td>
</tr>
<tr>
<td align="center" colspan="1">18 to 24</td>
<td align="center" colspan="1">5 additional cases</td>
</tr>
<tr>
<td align="center"></td>
<td align="center" rowspan="1">Decreases Compared to Placebo</td>
</tr>
<tr>
<td align="center" colspan="1">25 to 64</td>
<td align="center" colspan="1">1 fewer case</td>
</tr>
<tr class="Last">
<td align="center" colspan="1">≥65</td>
<td align="center" colspan="1">6 fewer cases</td>
</tr>
</tbody>
</table>
</div>
<p>No suicides occurred in any of the pediatric trials. There were
suicides in the adult trials, but the number was not sufficient to
reach any conclusion about drug effect on suicide.</p>
<p>It is unknown whether the suicidality risk extends to
longer-term use, i.e., beyond several months. However, there is
substantial evidence from placebo-controlled maintenance trials in
adults with depression that the use of antidepressants can delay
the recurrence of depression.</p>
<p><span class="Bold">All patients being treated with
antidepressants for any indication should be monitored
appropriately and observed closely for clinical worsening,
suicidality, and unusual changes in behavior, especially during the
initial few months of a course of drug therapy, or at times of dose
changes, either increases or decreases</span>.</p>
<p>The following symptoms, anxiety, agitation, panic attacks,
insomnia, irritability, hostility, aggressiveness, impulsivity,
akathisia (psychomotor restlessness), hypomania, and mania, have
been reported in adult and pediatric patients being treated with
antidepressants for major depressive disorder as well as for other
indications, both psychiatric and nonpsychiatric. Although a causal
link between the emergence of such symptoms and either the
worsening of depression and/or the emergence of suicidal impulses
has not been established, there is concern that such symptoms may
represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic
regimen, including possibly discontinuing the medication, in
patients whose depression is persistently worse, or who are
experiencing emergent suicidality or symptoms that might be
precursors to worsening depression or suicidality, especially if
these symptoms are severe, abrupt in onset, or were not part of the
patient's presenting symptoms.</p>
<p>If the decision has been made to discontinue treatment,
medication should be tapered, as rapidly as is feasible, but with
recognition that abrupt discontinuation can be associated with
certain symptoms (see <span class="Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS</a></span> and
<span class="Bold"><a href=
"#_305DC541-8AB2-7CBF-8D1C-0360CB638700">DOSAGE AND ADMINISTRATION,
Discontinuation of Treatment with Paroxetine</a></span>, for a
description of the risks of discontinuation of paroxetine).</p>
<p><span class="Bold">Families and caregivers of patients being
treated with antidepressants for major depressive disorder or other
indications, both psychiatric and nonpsychiatric, should be alerted
about the need to monitor patients for the emergence of agitation,
irritability, unusual changes in behavior, and the other symptoms
described above, as well as the emergence of suicidality, and to
report such symptoms immediately to healthcare providers. Such
monitoring should include daily observation by families and
caregivers.</span> Prescriptions for paroxetine should be written
for the smallest quantity of tablets consistent with good patient
management, in order to reduce the risk of overdose.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_7DDD1594-F019-03E5-88E9-D4A0DB16D38E" id=
"_7DDD1594-F019-03E5-88E9-D4A0DB16D38E"></a> <a name="section-5.2"
id="section-5.2"></a>
<h2>Screening Patients for Bipolar Disorder</h2>
<p class="First">A major depressive episode may be the initial
presentation of bipolar disorder. It is generally believed (though
not established in controlled trials) that treating such an episode
with an antidepressant alone may increase the likelihood of
precipitation of a mixed/manic episode in patients at risk for
bipolar disorder. Whether any of the symptoms described above
represent such a conversion is unknown. However, prior to
initiating treatment with an antidepressant, patients with
depressive symptoms should be adequately screened to determine if
they are at risk for bipolar disorder; such screening should
include a detailed psychiatric history, including a family history
of suicide, bipolar disorder, and depression. It should be noted
that paroxetine is not approved for use in treating bipolar
depression.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_7DC54B25-4FEC-BD4E-D55E-64872C6346CC" id=
"_7DC54B25-4FEC-BD4E-D55E-64872C6346CC"></a> <a name="section-5.3"
id="section-5.3"></a>
<h2><span class="Bold Italics">Serotonin Syndrome</span></h2>
<p class="First">The development of a potentially life-threatening
serotonin syndrome has been reported with SNRIs and SSRIs,
including paroxetine tablets, alone but particularly with
concomitant use of other serotonergic drugs (including triptans,
tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan,
buspirone, and St. John’s Wort) and with drugs that impair
metabolism of serotonin (in particular, MAOIs, both those intended
to treat psychiatric disorders and also others, such as linezolid
and intravenous methylene blue).</p>
<p>Serotonin syndrome symptoms may include mental status changes
(e.g., agitation, hallucinations, delirium, and coma), autonomic
instability (e.g., tachycardia, labile blood pressure, dizziness,
diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g.,
tremor, rigidity, myoclonus, hyperreflexia, incoordination),
seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting,
diarrhea). Patients should be monitored for the emergence of
serotonin syndrome.</p>
<p>The concomitant use of paroxetine with MAOIs intended to treat
psychiatric disorders is contraindicated. Paroxetine should also
not be started in a patient who is being treated with MAOIs such as
linezolid or intravenous methylene blue. All reports with methylene
blue that provided information on the route of administration
involved intravenous administration in the dose range of 1 mg/kg to
8 mg/kg. No reports involved the administration of methylene blue
by other routes (such as oral tablets or local tissue injection) or
at lower doses. There may be circumstances when it is necessary to
initiate treatment with an MAOI such as linezolid or intravenous
methylene blue in a patient taking paroxetine. Paroxetine should be
discontinued before initiating treatment with the MAOI (see
<span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>
and <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
<p>If concomitant use of paroxetine tablets with certain other
serotonergic drugs, i.e., triptans, tricyclic antidepressants,
fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John’s
Wort is clinically warranted, be aware of a potential increased
risk for serotonin syndrome, particularly during treatment
initiation and dose increases.</p>
<p><span class="Bold">Treatment with paroxetine tablets and any
concomitant serotonergic agents should be discontinued immediately
if the above events occur and supportive symptomatic treatment
should be initiated.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_aa498ea0-8db9-b87a-f82e-0cc24b035f32" id=
"_aa498ea0-8db9-b87a-f82e-0cc24b035f32"></a> <a name="section-5.4"
id="section-5.4"></a>
<h2><span class="Bold">Angle-Closure Glaucoma</span></h2>
<p class="First">The pupillary dilation that occurs following use
of many antidepressant drugs including paroxetine tablets may
trigger an angle closure attack in a patient with anatomically
narrow angles who does not have a patent iridectomy.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_C14ECFC4-54B5-D167-96D2-202875C809D4" id=
"_C14ECFC4-54B5-D167-96D2-202875C809D4"></a> <a name="section-5.5"
id="section-5.5"></a>
<h2>Potential Interaction With Thioridazine</h2>
<p class="First"><span class="Bold">Thioridazine administration
alone produces prolongation of the QTc interval, which is
associated with serious ventricular arrhythmias, such as torsade de
pointes</span>−<span class="Bold">type arrhythmias, and sudden
death. This effect appears to be dose related.</span></p>
<p><span class="Bold">An</span> <span class="Bold Italics">in
vivo</span> <span class="Bold">study suggests that drugs which
inhibit CYP2D6, such as paroxetine, will elevate plasma levels of
thioridazine. Therefore, it is recommended that paroxetine not be
used in combination with thioridazine (see <a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a> and
<a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS</a></span><span class="Bold">).</span></p>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"_32496B99-5D5B-EA6B-A064-AA7FA71F079B" id=
"_32496B99-5D5B-EA6B-A064-AA7FA71F079B"></a> <a name="section-5.6"
id="section-5.6"></a>
<h2>Usage in Pregnancy</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="34077-8"><a name=
"_1E7F55FB-4E9E-CE77-B2B7-B78DB2FDD281" id=
"_1E7F55FB-4E9E-CE77-B2B7-B78DB2FDD281"></a> <a name=
"section-5.6.1" id="section-5.6.1"></a>
<h3><span class="Bold Italics">Teratogenic Effects</span></h3>
<p class="First">Epidemiological studies have shown that infants
exposed to paroxetine in the first trimester of pregnancy have an
increased risk of congenital malformations, particularly
cardiovascular malformations. The findings from these studies are
summarized below:</p>
<ul>
<li>A study based on Swedish national registry data demonstrated
that infants exposed to paroxetine during pregnancy (n = 815) had
an increased risk of cardiovascular malformations (2% risk in
paroxetine-exposed infants) compared to the entire registry
population (1 % risk), for an odds ratio (OR) of 1.8 (95%
confidence interval 1.1 to 2.8). No increase in the risk of overall
congenital malformations was seen in the paroxetine-exposed
infants. The cardiac malformations in the paroxetine-exposed
infants were primarily ventricular septal defects (VSDs) and atrial
septal defects (ASDs). Septal defects range in severity from those
that resolve spontaneously to those which require surgery.</li>
<li>A separate retrospective cohort study from the United States
(United Healthcare data) evaluated 5,956 infants of mothers
dispensed antidepressants during the first trimester (n = 815 for
paroxetine). This study showed a trend towards an increased risk
for cardiovascular malformations for paroxetine (risk of 1.5%)
compared to other antidepressants (risk of 1%), for an OR of 1.5
(95% confidence interval 0.8 to 2.9). Of the 12 paroxetine-exposed
infants with cardiovascular malformations, 9 had VSDs. This study
also suggested an increased risk of overall major congenital
malformations including cardiovascular defects for paroxetine (4%
risk) compared to other (2% risk) antidepressants (OR 1.8; 95%
confidence interval 1.2 to 2.8).</li>
<li>Two large case-control studies using separate databases, each
with &gt;9,000 birth defect cases and &gt;4,000 controls, found
that maternal use of paroxetine during the first trimester of
pregnancy was associated with a 2- to 3-fold increased risk of
right ventricular outflow tract obstructions. In one study the odds
ratio was 2.5 (95% confidence interval, 1.0 to 6.0, 7 exposed
infants) and in the other study the odds ratio was 3.3 (95%
confidence interval, 1.3 to 8.8, 6 exposed infants).</li>
</ul>
<p>Other studies have found varying results as to whether there was
an increased risk of overall, cardiovascular, or specific
congenital malformations. A meta-analysis of epidemiological data
over a 16-year period (1992 to 2008) on first trimester paroxetine
use in pregnancy and congenital malformations included the
above-noted studies in addition to others (n = 17 studies that
included overall malformations and n = 14 studies that included
cardiovascular malformations; n = 20 distinct studies). While
subject to limitations, this meta-analysis suggested an increased
occurrence of cardiovascular malformations (prevalence odds ratio
[POR] 1.5; 95% confidence interval 1.2 to 1.9) and overall
malformations (POR 1.2; 95% confidence interval 1.1 to 1.4) with
paroxetine use during the first trimester. It was not possible in
this meta-analysis to determine the extent to which the observed
prevalence of cardiovascular malformations might have contributed
to that of overall malformations, nor was it possible to determine
whether any specific types of cardiovascular malformations might
have contributed to the observed prevalence of all cardiovascular
malformations.</p>
<p>If a patient becomes pregnant while taking paroxetine, she
should be advised of the potential harm to the fetus. Unless the
benefits of paroxetine to the mother justify continuing treatment,
consideration should be given to either discontinuing paroxetine
therapy or switching to another antidepressant (see <span class=
"Bold"><a href=
"#_471FA080-2874-DD56-3EDE-FA8ED06FA727">PRECAUTIONS,</a></span>
<span class="Bold Italics"><a href=
"#_471FA080-2874-DD56-3EDE-FA8ED06FA727">Discontinuation of
Treatment With Paroxetine</a></span><span class="Bold">)</span>.
For women who intend to become pregnant or are in their first
trimester of pregnancy, paroxetine should only be initiated after
consideration of the other available treatment options.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_4C8A4FE9-D20A-B44C-FBBC-7A2A242ED91B" id=
"_4C8A4FE9-D20A-B44C-FBBC-7A2A242ED91B"></a> <a name=
"section-5.6.2" id="section-5.6.2"></a>
<h3><span class="Bold Italics">Animal Findings</span></h3>
<p class="First">Reproduction studies were performed at doses up to
50 mg/kg/day in rats and 6 mg/kg/day in rabbits administered during
organogenesis. These doses are approximately 8 (rat) and 2 (rabbit)
times the maximum recommended human dose (MRHD) on an
mg/m<span class="Sup">2</span> basis. These studies have revealed
no evidence of teratogenic effects. However, in rats, there was an
increase in pup deaths during the first 4 days of lactation when
dosing occurred during the last trimester of gestation and
continued throughout lactation. This effect occurred at a dose of 1
mg/kg/day or approximately one-sixth of the MRHD on an
mg/m<span class="Sup">2</span> basis. The no-effect dose for rat
pup mortality was not determined. The cause of these deaths is not
known.</p>
</div>
<div class="Section" data-sectioncode="34078-6"><a name=
"_799918B4-28CC-8318-A9D2-CE2442B3F37A" id=
"_799918B4-28CC-8318-A9D2-CE2442B3F37A"></a> <a name=
"section-5.6.3" id="section-5.6.3"></a>
<h3><span class="Bold Italics">Nonteratogenic Effects</span></h3>
<p class="First">Neonates exposed to paroxetine hydrochloride and
other SSRIs or serotonin and norepinephrine reuptake inhibitors
(SNRIs), late in the third trimester have developed complications
requiring prolonged hospitalization, respiratory support, and tube
feeding. Such complications can arise immediately upon delivery.
Reported clinical findings have included respiratory distress,
cyanosis, apnea, seizures, temperature instability, feeding
difficulty, vomiting, hypoglycemia, hypotonia, hypertonia,
hyperreflexia, tremor, jitteriness, irritability, and constant
crying. These features are consistent with either a direct toxic
effect of SSRIs and SNRIs or, possibly, a drug discontinuation
syndrome. It should be noted that, in some cases, the clinical
picture is consistent with serotonin syndrome (see <span class=
"Bold"><a href="#_7DC54B25-4FEC-BD4E-D55E-64872C6346CC">WARNINGS,
Serotonin Syndrome</a></span>).</p>
<p>Infants exposed to SSRIs in pregnancy may have an increased risk
for persistent pulmonary hypertension of the newborn (PPHN). PPHN
occurs in 1 to 2 per 1,000 live births in the general population
and is associated with substantial neonatal morbidity and
mortality. Several recent epidemiologic studies suggest a positive
statistical association between SSRI use (including paroxetine
tablets, USP) in pregnancy and PPHN. Other studies do not show a
significant statistical association.</p>
<p>Physicians should also note the results of a prospective
longitudinal study of 201 pregnant women with a history of major
depression, who were either on antidepressants or had received
antidepressants less than 12 weeks prior to their last menstrual
period, and were in remission. Women who discontinued
antidepressant medication during pregnancy showed a significant
increase in relapse of their major depression compared to those
women who remained on antidepressant medication throughout
pregnancy.</p>
<p>When treating a pregnant woman with paroxetine tablets, the
physician should carefully consider both the potential risks of
taking an SSRI, along with the established benefits of treating
depression with an antidepressant. This decision can only be made
on a case by case basis (see <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span> and <span class="Bold"><a href=
"#_0A4013DB-7E48-5552-2F7C-B44B4DA4013D">ADVERSE REACTIONS,</a>
<a href="#_2240740F-F4CF-D15F-14B6-E503FB5E3128">Postmarketing
Reports</a></span>).</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"42232-9"><a name="_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84" id=
"_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84"></a> <a name="section-6"
id="section-6"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="34072-9"><a name=
"_8A1932E3-1E8B-4228-B548-A3BBF50E00F2" id=
"_8A1932E3-1E8B-4228-B548-A3BBF50E00F2"></a> <a name="section-6.1"
id="section-6.1"></a>
<h2>General</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_73E393E8-116D-74E1-F72E-F18E40279ADC" id=
"_73E393E8-116D-74E1-F72E-F18E40279ADC"></a> <a name=
"section-6.1.1" id="section-6.1.1"></a>
<h3><span class="Bold Italics">Activation of
Mania/Hypomania</span></h3>
<p class="First">During premarketing testing, hypomania or mania
occurred in approximately 1.0% of unipolar patients treated with
paroxetine compared to 1.1% of active-control and 0.3% of
placebo-treated unipolar patients. In a subset of patients
classified as bipolar, the rate of manic episodes was 2.2% for
paroxetine and 11.6% for the combined active-control groups. As
with all drugs effective in the treatment of major depressive
disorder, paroxetine should be used cautiously in patients with a
history of mania.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_34CE1B8E-E840-15B3-B35E-E2A8D82E42A9" id=
"_34CE1B8E-E840-15B3-B35E-E2A8D82E42A9"></a> <a name=
"section-6.1.2" id="section-6.1.2"></a>
<h3><span class="Bold Italics">Seizures</span></h3>
<p class="First">During premarketing testing, seizures occurred in
0.1% of patients treated with paroxetine, a rate similar to that
associated with other drugs effective in the treatment of major
depressive disorder. Paroxetine should be used cautiously in
patients with a history of seizures. It should be discontinued in
any patient who develops seizures.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_471FA080-2874-DD56-3EDE-FA8ED06FA727" id=
"_471FA080-2874-DD56-3EDE-FA8ED06FA727"></a> <a name=
"section-6.1.3" id="section-6.1.3"></a>
<h3><span class="Bold Italics">Discontinuation of Treatment With
Paroxetine</span></h3>
<p class="First">Recent clinical trials supporting the various
approved indications for paroxetine employed a taper-phase regimen,
rather than an abrupt discontinuation of treatment. The taper-phase
regimen used in GAD clinical trials involved an incremental
decrease in the daily dose by 10 mg/day at weekly intervals. When a
daily dose of 20 mg/day was reached, patients were continued on
this dose for 1 week before treatment was stopped.</p>
<p>With this regimen in those studies, the following adverse events
were reported at an incidence of 2% or greater for paroxetine and
were at least twice that reported for placebo: Abnormal dreams,
paresthesia, and dizziness. In the majority of patients, these
events were mild to moderate and were self-limiting and did not
require medical intervention.</p>
<p>During marketing of paroxetine and other SSRIs and SNRIs, there
have been spontaneous reports of adverse events occurring upon the
discontinuation of these drugs (particularly when abrupt),
including the following: Dysphoric mood, irritability, agitation,
dizziness, sensory disturbances (e.g., paresthesias such as
electric shock sensations and tinnitus), anxiety, confusion,
headache, lethargy, emotional lability, insomnia, and hypomania.
While these events are generally self-limiting, there have been
reports of serious discontinuation symptoms.</p>
<p>Patients should be monitored for these symptoms when
discontinuing treatment with paroxetine. A gradual reduction in the
dose rather than abrupt cessation is recommended whenever possible.
If intolerable symptoms occur following a decrease in the dose or
upon discontinuation of treatment, then resuming the previously
prescribed dose may be considered. Subsequently, the physician may
continue decreasing the dose but at a more gradual rate (see
<span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
<p>See also <span class="Bold"><a href=
"#_EF939498-0657-131F-4224-2C5AFE6FE462">PRECAUTIONS, Pediatric
Use</a></span>, for adverse events reported upon discontinuation of
treatment with paroxetine in pediatric patients.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_840ed5cf-486e-1d60-5504-ce15cca5f052" id=
"_840ed5cf-486e-1d60-5504-ce15cca5f052"></a> <a name=
"section-6.1.4" id="section-6.1.4"></a>
<h3><span class="Bold Italics">Tamoxifen</span></h3>
<p class="First">Some studies have shown that the efficacy of
tamoxifen, as measured by the risk of breast cancer
relapse/mortality, may be reduced when co-prescribed with
paroxetine as a result of paroxetine’s irreversible inhibition of
CYP2D6 (see <span class="Bold"><a href=
"#_ABAA2F32-1552-4C00-CA79-B42E5E3A2AD2">Drug
Interactions</a></span>). However, other studies have failed to
demonstrate such a risk. It is uncertain whether the
coadministration of paroxetine and tamoxifen has a significant
adverse effect on the efficacy of tamoxifen. One study suggests
that the risk may increase with longer duration of
coadministration. When tamoxifen is used for the treatment or
prevention of breast cancer, prescribers should consider using an
alternative antidepressant with little or no CYP2D6 inhibition.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_2497A8FF-5E2B-2AA8-978E-8C87A3CD3057" id=
"_2497A8FF-5E2B-2AA8-978E-8C87A3CD3057"></a> <a name=
"section-6.1.5" id="section-6.1.5"></a>
<h3><span class="Bold Italics">Akathisia</span></h3>
<p class="First">The use of paroxetine or other SSRIs has been
associated with the development of akathisia, which is
characterized by an inner sense of restlessness and psychomotor
agitation such as an inability to sit or stand still usually
associated with subjective distress. This is most likely to occur
within the first few weeks of treatment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_BE9894E9-F7FB-0FD4-D236-ECBD38C0BCCF" id=
"_BE9894E9-F7FB-0FD4-D236-ECBD38C0BCCF"></a> <a name=
"section-6.1.6" id="section-6.1.6"></a>
<h3><span class="Bold Italics">Hyponatremia</span></h3>
<p class="First">Hyponatremia may occur as a result of treatment
with SSRIs and SNRIs, including paroxetine. In many cases, this
hyponatremia appears to be the result of the syndrome of
inappropriate antidiuretic hormone secretion (SIADH). Cases with
serum sodium lower than 110 mmol/L have been reported. Elderly
patients may be at greater risk of developing hyponatremia with
SSRIs and SNRIs. Also, patients taking diuretics or who are
otherwise volume depleted may be at greater risk (see <span class=
"Bold"><a href=
"#_B838E495-9648-8271-E16E-0CE4A832896E">PRECAUTIONS, Geriatric
Use</a></span>). Discontinuation of paroxetine should be considered
in patients with symptomatic hyponatremia and appropriate medical
intervention should be instituted.</p>
<p>Signs and symptoms of hyponatremia include headache, difficulty
concentrating, memory impairment, confusion, weakness, and
unsteadiness, which may lead to falls. Signs and symptoms
associated with more severe and/or acute cases have included
hallucination, syncope, seizure, coma, respiratory arrest, and
death.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_2F0DAC37-590F-AE8E-61A0-69D3CC3C7FBC" id=
"_2F0DAC37-590F-AE8E-61A0-69D3CC3C7FBC"></a> <a name=
"section-6.1.7" id="section-6.1.7"></a>
<h3><span class="Bold Italics">Abnormal Bleeding</span></h3>
<p class="First">SSRIs and SNRIs, including paroxetine, may
increase the risk of bleeding events. Concomitant use of aspirin,
nonsteroidal anti-inflammatory drugs, warfarin, and other
anticoagulants may add to this risk. Case reports and
epidemiological studies (case-control and cohort design) have
demonstrated an association between use of drugs that interfere
with serotonin reuptake and the occurrence of gastrointestinal
bleeding. Bleeding events related to SSRIs and SNRIs use have
ranged from ecchymoses, hematomas, epistaxis, and petechiae to
life-threatening hemorrhages. Patients should be cautioned about
the risk of bleeding associated with the concomitant use of
paroxetine and NSAIDs, aspirin, or other drugs that affect
coagulation.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_0ff1d292-7b86-14b2-69ab-3fb4c95d568a" id=
"_0ff1d292-7b86-14b2-69ab-3fb4c95d568a"></a> <a name=
"section-6.1.8" id="section-6.1.8"></a>
<h3><span class="Bold Italics">Bone Fracture</span></h3>
<p class="First">Epidemiological studies on bone fracture risk
following exposure to some antidepressants, including SSRIs, have
reported an association between antidepressant treatment and
fractures. There are multiple possible causes for this observation
and it is unknown to what extent fracture risk is directly
attributable to SSRI treatment. The possibility of a pathological
fracture, that is, a fracture produced by minimal trauma in a
patient with decreased bone mineral density, should be considered
in patients treated with paroxetine who present with unexplained
bone pain, point tenderness, swelling, or bruising.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_BAB5B29C-923B-84AC-D108-8832456ACD43" id=
"_BAB5B29C-923B-84AC-D108-8832456ACD43"></a> <a name=
"section-6.1.9" id="section-6.1.9"></a>
<h3><span class="Bold Italics">Use in Patients With Concomitant
Illness</span></h3>
<p class="First">Clinical experience with paroxetine in patients
with certain concomitant systemic illness is limited. Caution is
advisable in using paroxetine in patients with diseases or
conditions that could affect metabolism or hemodynamic
responses.</p>
<p>As with other SSRIs, mydriasis has been infrequently reported in
premarketing studies with paroxetine. A few cases of acute angle
closure glaucoma associated with paroxetine therapy have been
reported in the literature. As mydriasis can cause acute angle
closure in patients with narrow angle glaucoma, caution should be
used when paroxetine is prescribed for patients with narrow angle
glaucoma.</p>
<p>Paroxetine has not been evaluated or used to any appreciable
extent in patients with a recent history of myocardial infarction
or unstable heart disease. Patients with these diagnoses were
excluded from clinical studies during the product’s premarket
testing. Evaluation of electrocardiograms of 682 patients who
received paroxetine in double-blind, placebo-controlled trials,
however, did not indicate that paroxetine is associated with the
development of significant ECG abnormalities. Similarly, paroxetine
does not cause any clinically important changes in heart rate or
blood pressure.</p>
<p>Increased plasma concentrations of paroxetine occur in patients
with severe renal impairment (creatinine clearance &lt;30 mL/min.)
or severe hepatic impairment. A lower starting dose should be used
in such patients (see <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"_259A88A0-AC95-16B2-8216-4981588ECC62" id=
"_259A88A0-AC95-16B2-8216-4981588ECC62"></a> <a name="section-6.2"
id="section-6.2"></a>
<h2>Information for Patients</h2>
<p class="First">Paroxetine tablets should not be chewed or
crushed, and should be swallowed whole.</p>
<p>Patients should be cautioned about the risk of serotonin
syndrome with the concomitant use of paroxetine and triptans,
tramadol, or other serotonergic agents.</p>
<p>Patients should be advised that taking paroxetine tablets can
cause mild pupillary dilation, which in susceptible individuals,
can lead to an episode of angle closure glaucoma. Pre-existing
glaucoma is almost always open-angle glaucoma because angle closure
glaucoma, when diagnosed, can be treated definitively with
iridectomy. Open-angle glaucoma is not a risk factor for angle
closure glaucoma. Patients may wish to be examined to determine
whether they are susceptible to angle closure, and have a
prophylactic procedure (e.g., iridectomy), if they are
susceptible.</p>
<p>Prescribers or other health professionals should inform
patients, their families, and their caregivers about the benefits
and risks associated with treatment with paroxetine and should
counsel them in its appropriate use. A patient Medication Guide is
available for paroxetine tablets. The prescriber or health
professional should instruct patients, their families, and their
caregivers to read the Medication Guide and should assist them in
understanding its contents. Patients should be given the
opportunity to discuss the contents of the Medication Guide and to
obtain answers to any questions they may have. The complete text of
the Medication Guide is reprinted at the end of this document.</p>
<p>Patients should be advised of the following issues and asked to
alert their prescriber if these occur while taking paroxetine
tablets</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9099EC88-27B0-22DA-982A-A6AF4788A9A9" id=
"_9099EC88-27B0-22DA-982A-A6AF4788A9A9"></a> <a name="section-6.3"
id="section-6.3"></a>
<h2>Clinical Worsening and Suicide Risk</h2>
<p class="First">Patients, their families, and their caregivers
should be encouraged to be alert to the emergence of anxiety,
agitation, panic attacks, insomnia, irritability, hostility,
aggressiveness, impulsivity, akathisia (psychomotor restlessness),
hypomania, mania, other unusual changes in behavior, worsening of
depression, and suicidal ideation, especially early during
antidepressant treatment and when the dose is adjusted up or down.
Families and caregivers of patients should be advised to look for
the emergence of such symptoms on a day-to-day basis, since changes
may be abrupt. Such symptoms should be reported to the patient's
prescriber or health professional, especially if they are severe,
abrupt in onset, or were not part of the patient's presenting
symptoms. Symptoms such as these may be associated with an
increased risk for suicidal thinking and behavior and indicate a
need for very close monitoring and possibly changes in the
medication.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_523A3D1F-A281-BB64-5110-C620350F9B50" id=
"_523A3D1F-A281-BB64-5110-C620350F9B50"></a> <a name=
"section-6.3.1" id="section-6.3.1"></a>
<h3><span class="Bold Italics">Drugs That Interfere With Hemostasis
(e.g., NSAIDs, Aspirin, and Warfarin)</span></h3>
<p class="First">Patients should be cautioned about the concomitant
use of paroxetine and NSAIDs, aspirin, warfarin, or other drugs
that affect coagulation since combined use of psychotropic drugs
that interfere with serotonin reuptake and these agents has been
associated with an increased risk of bleeding.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_B5CA3779-2533-23CC-0693-935ED41BC24B" id=
"_B5CA3779-2533-23CC-0693-935ED41BC24B"></a> <a name=
"section-6.3.2" id="section-6.3.2"></a>
<h3><span class="Bold Italics">Interference With Cognitive and
Motor Performance</span></h3>
<p class="First">Any psychoactive drug may impair judgment,
thinking, or motor skills. Although in controlled studies
paroxetine has not been shown to impair psychomotor performance,
patients should be cautioned about operating hazardous machinery,
including automobiles, until they are reasonably certain that
therapy with paroxetine does not affect their ability to engage in
such activities.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_E5E5E9B1-2120-4CAE-E0D8-42883E783EEE" id=
"_E5E5E9B1-2120-4CAE-E0D8-42883E783EEE"></a> <a name=
"section-6.3.3" id="section-6.3.3"></a>
<h3><span class="Bold Italics">Completing Course of
Therapy</span></h3>
<p class="First">While patients may notice improvement with
treatment with paroxetine in 1 to 4 weeks, they should be advised
to continue therapy as directed.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_1C372CA4-78E6-B48E-52E8-BDC29C570C69" id=
"_1C372CA4-78E6-B48E-52E8-BDC29C570C69"></a> <a name=
"section-6.3.4" id="section-6.3.4"></a>
<h3><span class="Bold Italics">Concomitant Medication</span></h3>
<p class="First">Patients should be advised to inform their
physician if they are taking, or plan to take, any prescription or
over-the-counter drugs, since there is a potential for
interactions.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_1CCC3522-0446-13D9-0DB7-E9C904D59353" id=
"_1CCC3522-0446-13D9-0DB7-E9C904D59353"></a> <a name=
"section-6.3.5" id="section-6.3.5"></a>
<h3><span class="Bold Italics">Alcohol</span></h3>
<p class="First">Although paroxetine has not been shown to increase
the impairment of mental and motor skills caused by alcohol,
patients should be advised to avoid alcohol while taking
paroxetine.</p>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"_2E65D211-6566-32B2-0BBA-623E4427B5EB" id=
"_2E65D211-6566-32B2-0BBA-623E4427B5EB"></a> <a name=
"section-6.3.6" id="section-6.3.6"></a>
<h3><span class="Bold Italics">Pregnancy</span></h3>
<p class="First">Patients should be advised to notify their
physician if they become pregnant or intend to become pregnant
during therapy (see <span class="Bold"><a href=
"#_1E7F55FB-4E9E-CE77-B2B7-B78DB2FDD281">WARNINGS,</a></span>
<span class="Bold"><a href=
"#_1E7F55FB-4E9E-CE77-B2B7-B78DB2FDD281">Usage in
Pregnancy:</a></span><span class="Bold Italics"><a href=
"#_1E7F55FB-4E9E-CE77-B2B7-B78DB2FDD281">Teratogenic
Effects</a></span> and <span class="Bold Italics"><a href=
"#_799918B4-28CC-8318-A9D2-CE2442B3F37A">Nonteratogenic
Effects</a></span><span class="Italics">)</span>.</p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"_6BAC19DC-EA3F-CF43-C6A5-86354A3F5F49" id=
"_6BAC19DC-EA3F-CF43-C6A5-86354A3F5F49"></a> <a name=
"section-6.3.7" id="section-6.3.7"></a>
<h3><span class="Bold Italics">Nursing</span></h3>
<p class="First">Patients should be advised to notify their
physician if they are breastfeeding an infant (see <span class=
"Bold"><a href=
"#_70780842-C467-7CA6-9818-38717469A2E3">PRECAUTIONS, Nursing
Mothers</a></span>).</p>
</div>
</div>
<div class="Section" data-sectioncode="34075-2"><a name=
"_EFA4BDA8-1C6E-F596-FCE0-0DDCFD75AC21" id=
"_EFA4BDA8-1C6E-F596-FCE0-0DDCFD75AC21"></a> <a name="section-6.4"
id="section-6.4"></a>
<h2>Laboratory Tests</h2>
<p class="First">There are no specific laboratory tests
recommended.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"_ABAA2F32-1552-4C00-CA79-B42E5E3A2AD2" id=
"_ABAA2F32-1552-4C00-CA79-B42E5E3A2AD2"></a> <a name="section-6.5"
id="section-6.5"></a>
<h2>Drug Interactions</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_F281C5C3-E49E-0031-D957-4538AFC041D9" id=
"_F281C5C3-E49E-0031-D957-4538AFC041D9"></a> <a name=
"section-6.5.1" id="section-6.5.1"></a>
<h3><span class="Bold Italics">Tryptophan</span></h3>
<p class="First">As with other serotonin reuptake inhibitors, an
interaction between paroxetine and tryptophan may occur when they
are coadministered. Adverse experiences, consisting primarily of
headache, nausea, sweating, and dizziness, have been reported when
tryptophan was administered to patients taking paroxetine.
Consequently, concomitant use of paroxetine with tryptophan is not
recommended (see <span class="Bold"><a href=
"#_7DC54B25-4FEC-BD4E-D55E-64872C6346CC">WARNINGS, Serotonin
Syndrome</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_691A7C43-BBD9-17EB-9B38-483F026B86E2" id=
"_691A7C43-BBD9-17EB-9B38-483F026B86E2"></a> <a name=
"section-6.5.2" id="section-6.5.2"></a>
<h3><span class="Bold Italics">Monoamine Oxidase
Inhibitors</span></h3>
<p class="First">See <span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>
and <span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_EBB352EA-3110-31E6-FCD8-407AF6AF77C5" id=
"_EBB352EA-3110-31E6-FCD8-407AF6AF77C5"></a> <a name=
"section-6.5.3" id="section-6.5.3"></a>
<h3><span class="Bold Italics">Pimozide</span></h3>
<p class="First">In a controlled study of healthy volunteers, after
paroxetine was titrated to 60 mg daily, co-administration of a
single dose of 2 mg pimozide was associated with mean increases in
pimozide AUC of 151% and C<span class="Sub">max</span> of 62%,
compared to pimozide administered alone. The increase in pimozide
AUC and C<span class="Sub">max</span> is due to the CYP2D6
inhibitory properties of paroxetine. Due to the narrow therapeutic
index of pimozide and its known ability to prolong the QT interval,
concomitant use of pimozide and paroxetine is contraindicated (see
<span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_22756770-B409-1106-0559-A586B432E335" id=
"_22756770-B409-1106-0559-A586B432E335"></a> <a name=
"section-6.5.4" id="section-6.5.4"></a>
<h3><span class="Bold Italics">Serotonergic Drugs</span></h3>
<p class="First">Based on the mechanism of action of SNRIs and
SSRIs, including paroxetine hydrochloride, and the potential for
serotonin syndrome, caution is advised when paroxetine is
coadministered with other drugs that may affect the serotonergic
neurotransmitter systems, such as triptans, lithium, fentanyl,
tramadol, or St. John's Wort (see <span class="Bold"><a href=
"#_7DC54B25-4FEC-BD4E-D55E-64872C6346CC">WARNINGS, Serotonin
Syndrome</a></span>).</p>
<p>The concomitant use of paroxetine with MAOIs (including
linezolid and intravenous methylene blue) is contraindicated (see
<span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>).
The concomitant use of paroxetine with other SSRIs, SNRIs or
tryptophan is not recommended (see <span class="Bold"><a href=
"#_F281C5C3-E49E-0031-D957-4538AFC041D9">PRECAUTIONS, Drug
Interactions,</a></span><span class="Bold Italics"><a href=
"#_F281C5C3-E49E-0031-D957-4538AFC041D9">Tryptophan</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_A7E95408-21EB-4D79-066A-D5DD117B363A" id=
"_A7E95408-21EB-4D79-066A-D5DD117B363A"></a> <a name=
"section-6.5.5" id="section-6.5.5"></a>
<h3><span class="Bold Italics">Thioridazine</span></h3>
<p class="First">See <span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>
and <span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_186561AE-9DD2-D930-F82B-B075E52CBA1E" id=
"_186561AE-9DD2-D930-F82B-B075E52CBA1E"></a> <a name=
"section-6.5.6" id="section-6.5.6"></a>
<h3><span class="Bold Italics">Warfarin</span></h3>
<p class="First">Preliminary data suggest that there may be a
pharmacodynamic interaction (that causes an increased bleeding
diathesis in the face of unaltered prothrombin time) between
paroxetine and warfarin. Since there is little clinical experience,
the concomitant administration of paroxetine and warfarin should be
undertaken with caution (see <span class="Bold"><a href=
"#_053106DC-FA15-C683-88BC-08E7E0287160">PRECAUTIONS</a></span><span class="Bold">,</span>
<span class="Bold Italics"><a href=
"#_523A3D1F-A281-BB64-5110-C620350F9B50"></a><a href=
"#_053106DC-FA15-C683-88BC-08E7E0287160">Drugs</a><a href=
"#_523A3D1F-A281-BB64-5110-C620350F9B50">That Interfere With
Hemostasis</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_CC0FDE05-5232-9148-B747-372C5671722F" id=
"_CC0FDE05-5232-9148-B747-372C5671722F"></a> <a name=
"section-6.5.7" id="section-6.5.7"></a>
<h3><span class="Bold Italics">Triptans</span></h3>
<p class="First">There have been rare postmarketing reports of
serotonin syndrome with the use of an SSRI and a triptan. If
concomitant use of paroxetine with a triptan is clinically
warranted, careful observation of the patient is advised,
particularly during treatment initiation and dose increases (see
<span class="Bold"><a href=
"#_7DC54B25-4FEC-BD4E-D55E-64872C6346CC">WARNINGS, Serotonin
Syndrome</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_12481F8B-AC71-B07A-FE5D-0E447291E9BB" id=
"_12481F8B-AC71-B07A-FE5D-0E447291E9BB"></a> <a name=
"section-6.5.8" id="section-6.5.8"></a>
<h3><span class="Bold Italics">Drugs Affecting Hepatic
Metabolism</span></h3>
<p class="First">The metabolism and pharmacokinetics of paroxetine
may be affected by the induction or inhibition of drug-metabolizing
enzymes.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_31D9B30A-16DC-3FB4-9805-605C822C7789" id=
"_31D9B30A-16DC-3FB4-9805-605C822C7789"></a> <a name=
"section-6.5.9" id="section-6.5.9"></a>
<h3><span class="Bold Italics">Cimetidine</span></h3>
<p class="First">Cimetidine inhibits many cytochrome P<span class=
"Sub">450</span> (oxidative) enzymes. In a study where paroxetine
(30 mg once daily) was dosed orally for 4 weeks, steady-state
plasma concentrations of paroxetine were increased by approximately
50% during coadministration with oral cimetidine (300 mg three
times daily) for the final week. Therefore, when these drugs are
administered concurrently, dosage adjustment of paroxetine after
the 20-mg starting dose should be guided by clinical effect. The
effect of paroxetine on cimetidine's pharmacokinetics was not
studied.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_47CB6621-2ECE-E667-45F4-08AE1EB95198" id=
"_47CB6621-2ECE-E667-45F4-08AE1EB95198"></a> <a name=
"section-6.5.10" id="section-6.5.10"></a>
<h3><span class="Bold Italics">Phenobarbital</span></h3>
<p class="First">Phenobarbital induces many cytochrome
P<span class="Sub">450</span> (oxidative) enzymes. When a single
oral 30-mg dose of paroxetine was administered at phenobarbital
steady state (100 mg once daily for 14 days), paroxetine AUC and T½
were reduced (by an average of 25% and 38%, respectively) compared
to paroxetine administered alone. The effect of paroxetine on
phenobarbital pharmacokinetics was not studied. Since paroxetine
exhibits nonlinear pharmacokinetics, the results of this study may
not address the case where the 2 drugs are both being chronically
dosed. No initial dosage adjustment of paroxetine is considered
necessary when coadministered with phenobarbital; any subsequent
adjustment should be guided by clinical effect.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D67BFD03-3343-8AD0-830A-C789B8BEC1D1" id=
"_D67BFD03-3343-8AD0-830A-C789B8BEC1D1"></a> <a name=
"section-6.5.11" id="section-6.5.11"></a>
<h3><span class="Bold Italics">Phenytoin</span></h3>
<p class="First">When a single oral 30-mg dose of paroxetine was
administered at phenytoin steady state (300 mg once daily for 14
days), paroxetine AUC and T½ were reduced (by an average of 50% and
35%, respectively) compared to paroxetine administered alone. In a
separate study, when a single oral 300-mg dose of phenytoin was
administered at paroxetine steady state (30 mg once daily for 14
days), phenytoin AUC was slightly reduced (12% on average) compared
to phenytoin administered alone. Since both drugs exhibit nonlinear
pharmacokinetics, the above studies may not address the case where
the 2 drugs are both being chronically dosed. No initial dosage
adjustments are considered necessary when these drugs are
coadministered; any subsequent adjustments should be guided by
clinical effect (see <span class="Bold"><a href=
"#_2240740F-F4CF-D15F-14B6-E503FB5E3128">ADVERSE REACTIONS,
Postmarketing Reports</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_137839A3-9D2C-505E-4B61-B3E9FE8E27AF" id=
"_137839A3-9D2C-505E-4B61-B3E9FE8E27AF"></a> <a name=
"section-6.5.12" id="section-6.5.12"></a>
<h3><span class="Bold Italics">Drugs Metabolized by
CYP2D6</span></h3>
<p class="First">Many drugs, including most drugs effective in the
treatment of major depressive disorder (paroxetine, other SSRIs and
many tricyclics), are metabolized by the cytochrome P<span class=
"Sub">450</span> isozyme CYP2D6. Like other agents that are
metabolized by CYP2D6, paroxetine may significantly inhibit the
activity of this isozyme. In most patients (&gt;90%), this CYP2D6
isozyme is saturated early during dosing with paroxetine. In 1
study, daily dosing of paroxetine (20 mg once daily) under
steady-state conditions increased single dose desipramine (100 mg)
C<span class="Sub">max</span>, AUC, and T<span class="Sub">½</span>
by an average of approximately 2-, 5-, and 3-fold, respectively.
Concomitant use of paroxetine with risperidone, a CYP2D6 substrate
has also been evaluated. In 1 study, daily dosing of paroxetine 20
mg in patients stabilized on risperidone (4 to 8 mg/day) increased
mean plasma concentrations of risperidone approximately 4-fold,
decreased 9-hydroxyrisperidone concentrations approximately 10%,
and increased concentrations of the active moiety (the sum of
risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The
effect of paroxetine on the pharmacokinetics of atomoxetine has
been evaluated when both drugs were at steady state. In healthy
volunteers who were extensive metabolizers of CYP2D6, paroxetine 20
mg daily was given in combination with 20 mg atomoxetine every 12
hours. This resulted in increases in steady state atomoxetine AUC
values that were 6- to 8-fold greater and in atomoxetine
C<span class="Sub">max</span> values that were 3- to 4-fold greater
than when atomoxetine was given alone. Dosage adjustment of
atomoxetine may be necessary and it is recommended that atomoxetine
be initiated at a reduced dose when it is given with
paroxetine.</p>
<p>Concomitant use of paroxetine with other drugs metabolized by
cytochrome CYP2D6 has not been formally studied but may require
lower doses than usually prescribed for either paroxetine or the
other drug.</p>
<p>Therefore, coadministration of paroxetine with other drugs that
are metabolized by this isozyme, including certain drugs effective
in the treatment of major depressive disorder (e.g., nortriptyline,
amitriptyline, imipramine, desipramine, and fluoxetine),
phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g.,
propafenone, flecainide, and encainide), or that inhibit this
enzyme (e.g., quinidine), should be approached with caution.</p>
<p>However, due to the risk of serious ventricular arrhythmias and
sudden death potentially associated with elevated plasma levels of
thioridazine, paroxetine and thioridazine should not be
coadministered (see <span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>
and <span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span>).</p>
<p>Tamoxifen is a pro-drug requiring metabolic activation by
CYP2D6. Inhibition of CYP2D6 by paroxetine may lead to reduced
plasma concentrations of an active metabolite (endoxifen) and hence
reduced efficacy of tamoxifen (see <span class="Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS</a></span>).</p>
<p>At steady state, when the CYP2D6 pathway is essentially
saturated, paroxetine clearance is governed by alternative
P<span class="Sub">450</span> isozymes that, unlike CYP2D6, show no
evidence of saturation (see <span class="Bold"><a href=
"#_43B2F5D8-0F35-F4FC-D11A-318885931F63">PRECAUTIONS,</a></span>
<span class="Bold Italics"><a href=
"#_43B2F5D8-0F35-F4FC-D11A-318885931F63">Tricyclic
Antidepressants</a> <a href=
"#_43B2F5D8-0F35-F4FC-D11A-318885931F63">[TCAs]</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_EB6A5107-B86F-F470-348B-CF35F9F9A0CA" id=
"_EB6A5107-B86F-F470-348B-CF35F9F9A0CA"></a> <a name=
"section-6.5.13" id="section-6.5.13"></a>
<h3><span class="Bold Italics">Drugs Metabolized by Cytochrome
CYP3A4</span></h3>
<p class="First">An <span class="Italics">in vivo</span>
interaction study involving the coadministration under steady-state
conditions of paroxetine and terfenadine, a substrate for
cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine
pharmacokinetics. In addition, <span class="Italics">in
vitro</span> studies have shown ketoconazole, a potent inhibitor of
CYP3A4 activity, to be at least 100 times more potent than
paroxetine as an inhibitor of the metabolism of several substrates
for this enzyme, including terfenadine, astemizole, cisapride,
triazolam, and cyclosporine. Based on the assumption that the
relationship between paroxetine’s <span class="Italics">in
vitro</span> K<span class="Sub">i</span> and its lack of effect on
terfenadine’s <span class="Italics">in vivo</span> clearance
predicts its effect on other CYP3A4 substrates, paroxetine’s extent
of inhibition of CYP3A4 activity is not likely to be of clinical
significance.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_43B2F5D8-0F35-F4FC-D11A-318885931F63" id=
"_43B2F5D8-0F35-F4FC-D11A-318885931F63"></a> <a name=
"section-6.5.14" id="section-6.5.14"></a>
<h3><span class="Bold Italics">Tricyclic Antidepressants
(TCAs)</span></h3>
<p class="First">Caution is indicated in the coadministration of
tricyclic antidepressants (TCAs) with paroxetine, because
paroxetine may inhibit TCA metabolism. Plasma TCA concentrations
may need to be monitored, and the dose of TCA may need to be
reduced, if a TCA is coadministered with paroxetine (see
<span class="Bold"><a href=
"#_EB6A5107-B86F-F470-348B-CF35F9F9A0CA">PRECAUTIONS,</a></span>
<span class="Bold Italics"><a href=
"#_EB6A5107-B86F-F470-348B-CF35F9F9A0CA">Drugs Metabolized by
Cytochrome CYP2D6</a></span><span class="Bold">)</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_EDC8B814-5EE2-F5DA-CF7A-2ED78CCECD4C" id=
"_EDC8B814-5EE2-F5DA-CF7A-2ED78CCECD4C"></a> <a name=
"section-6.5.15" id="section-6.5.15"></a>
<h3><span class="Bold Italics">Drugs Highly Bound to Plasma
Protein</span></h3>
<p class="First">Because paroxetine is highly bound to plasma
protein, administration of paroxetine to a patient taking another
drug that is highly protein bound may cause increased free
concentrations of the other drug, potentially resulting in adverse
events. Conversely, adverse effects could result from displacement
of paroxetine by other highly bound drugs.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_053106DC-FA15-C683-88BC-08E7E0287160" id=
"_053106DC-FA15-C683-88BC-08E7E0287160"></a> <a name=
"section-6.5.16" id="section-6.5.16"></a>
<h3><span class="Bold Italics">Drugs That Interfere With Hemostasis
(e.g., NSAIDs, Aspirin, and Warfarin)</span></h3>
<p class="First">Serotonin release by platelets plays an important
role in hemostasis. Epidemiological studies of the case-control and
cohort design that have demonstrated an association between use of
psychotropic drugs that interfere with serotonin reuptake and the
occurrence of upper gastrointestinal bleeding have also shown that
concurrent use of an NSAID or aspirin may potentiate this risk of
bleeding. Altered anticoagulant effects, including increased
bleeding, have been reported when SSRIs or SNRIs are coadministered
with warfarin. Patients receiving warfarin therapy should be
carefully monitored when paroxetine is initiated or
discontinued.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D00E3E42-7257-4B60-53A6-50BC5BEF49FD" id=
"_D00E3E42-7257-4B60-53A6-50BC5BEF49FD"></a> <a name=
"section-6.5.17" id="section-6.5.17"></a>
<h3><span class="Bold Italics">Alcohol</span></h3>
<p class="First">Although paroxetine does not increase the
impairment of mental and motor skills caused by alcohol, patients
should be advised to avoid alcohol while taking paroxetine.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_09E316A9-DA60-B766-13BF-6ECD0869DEBF" id=
"_09E316A9-DA60-B766-13BF-6ECD0869DEBF"></a> <a name=
"section-6.5.18" id="section-6.5.18"></a>
<h3><span class="Bold Italics">Lithium</span></h3>
<p class="First">A multiple-dose study has shown that there is no
pharmacokinetic interaction between paroxetine and lithium
carbonate. However, due to the potential for serotonin syndrome,
caution is advised when paroxetine is coadministered with
lithium.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_352EBCA4-BE6D-A5EC-EC94-CE096E3D9894" id=
"_352EBCA4-BE6D-A5EC-EC94-CE096E3D9894"></a> <a name=
"section-6.5.19" id="section-6.5.19"></a>
<h3><span class="Bold Italics">Digoxin</span></h3>
<p class="First">The steady-state pharmacokinetics of paroxetine
was not altered when administered with digoxin at steady state.
Mean digoxin AUC at steady state decreased by 15% in the presence
of paroxetine. Since there is little clinical experience, the
concurrent administration of paroxetine and digoxin should be
undertaken with caution.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_7894B401-F089-5329-72D1-9BCA42E6DE2A" id=
"_7894B401-F089-5329-72D1-9BCA42E6DE2A"></a> <a name=
"section-6.5.20" id="section-6.5.20"></a>
<h3><span class="Bold Italics">Diazepam</span></h3>
<p class="First">Under steady-state conditions, diazepam does not
appear to affect paroxetine kinetics. The effects of paroxetine on
diazepam were not evaluated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_A3D214EA-6A76-00F3-9303-254A21E13439" id=
"_A3D214EA-6A76-00F3-9303-254A21E13439"></a> <a name=
"section-6.5.21" id="section-6.5.21"></a>
<h3><span class="Bold Italics">Procyclidine</span></h3>
<p class="First">Daily oral dosing of paroxetine (30 mg once daily)
increased steady-state AUC<span class="Sub">0-24</span>,
C<span class="Sub">max</span>, and C<span class="Sub">min</span>
values of procyclidine (5 mg oral once daily) by 35%, 37% and 67%,
respectively, compared to procyclidine alone at steady state. If
anticholinergic effects are seen, the dose of procyclidine should
be reduced.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_F47521FF-92B6-A35C-4AA4-D2739B5DBC32" id=
"_F47521FF-92B6-A35C-4AA4-D2739B5DBC32"></a> <a name=
"section-6.5.22" id="section-6.5.22"></a>
<h3><span class="Bold Italics">Beta-Blockers</span></h3>
<p class="First">In a study where propranolol (80 mg twice daily)
was dosed orally for 18 days, the established steady-state plasma
concentrations of propranolol were unaltered during
coadministration with paroxetine (30 mg once daily) for the final
10 days. The effects of propranolol on paroxetine have not been
evaluated (see <span class="Bold"><a href=
"#_2240740F-F4CF-D15F-14B6-E503FB5E3128">ADVERSE REACTIONS,
Postmarketing Reports</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_4EC52903-6308-9335-5E04-46828E8183A2" id=
"_4EC52903-6308-9335-5E04-46828E8183A2"></a> <a name=
"section-6.5.23" id="section-6.5.23"></a>
<h3><span class="Bold Italics">Theophylline</span></h3>
<p class="First">Reports of elevated theophylline levels associated
with treatment with paroxetine have been reported. While this
interaction has not been formally studied, it is recommended that
theophylline levels be monitored when these drugs are concurrently
administered.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_3FCB7D37-15F5-185C-E1D2-4E641097E4A6" id=
"_3FCB7D37-15F5-185C-E1D2-4E641097E4A6"></a> <a name=
"section-6.5.24" id="section-6.5.24"></a>
<h3><span class="Bold Italics">Fosamprenavir/Ritonavir</span></h3>
<p class="First">Co-administration of fosamprenavir/ritonavir with
paroxetine significantly decreased plasma levels of paroxetine. Any
dose adjustment should be guided by clinical effect (tolerability
and efficacy).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_6FAFA6F9-8486-6839-C476-ACBABB16F11E" id=
"_6FAFA6F9-8486-6839-C476-ACBABB16F11E"></a> <a name=
"section-6.5.25" id="section-6.5.25"></a>
<h3><span class="Bold Italics">Electroconvulsive Therapy
(ECT)</span></h3>
<p class="First">There are no clinical studies of the combined use
of ECT and paroxetine.</p>
</div>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"_00CFA8CA-40AC-7016-D9CA-D52EEE1DF0CE" id=
"_00CFA8CA-40AC-7016-D9CA-D52EEE1DF0CE"></a> <a name="section-6.6"
id="section-6.6"></a>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_7F72C376-BA17-4753-138F-2B01CF1581AE" id=
"_7F72C376-BA17-4753-138F-2B01CF1581AE"></a> <a name=
"section-6.6.1" id="section-6.6.1"></a>
<h3><span class="Bold Italics">Carcinogenesis</span></h3>
<p class="First">Two-year carcinogenicity studies were conducted in
rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day
(mice) and 1, 5, and 20 mg/kg/day (rats). These doses are up to 2.4
(mouse) and 3.9 (rat) times the MRHD for major depressive disorder,
social anxiety disorder, and GAD on a mg/m<span class=
"Sup">2</span> basis. Because the MRHD for major depressive
disorder is slightly less than that for OCD (50 mg versus 60 mg),
the doses used in these carcinogenicity studies were only 2.0
(mouse) and 3.2 (rat) times the MRHD for OCD. There was a
significantly greater number of male rats in the high-dose group
with reticulum cell sarcomas (1/100, 0/50, 0/50, and 4/50 for
control, low-, middle-, and high-dose groups, respectively) and a
significantly increased linear trend across dose groups for the
occurrence of lymphoreticular tumors in male rats. Female rats were
not affected. Although there was a dose-related increase in the
number of tumors in mice, there was no drug-related increase in the
number of mice with tumors. The relevance of these findings to
humans is unknown.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_22179C9B-F94A-BFB1-BFC0-19900AA67195" id=
"_22179C9B-F94A-BFB1-BFC0-19900AA67195"></a> <a name=
"section-6.6.2" id="section-6.6.2"></a>
<h3><span class="Bold Italics">Mutagenesis</span></h3>
<p class="First">Paroxetine produced no genotoxic effects in a
battery of 5 <span class="Italics">in vitro</span> and 2
<span class="Italics">in vivo</span> assays that included the
following: Bacterial mutation assay, mouse lymphoma mutation assay,
unscheduled DNA synthesis assay, and tests for cytogenetic
aberrations <span class="Italics">in vivo</span> in mouse bone
marrow and <span class="Italics">in vitro</span> in human
lymphocytes and in a dominant lethal test in rats.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_5DBC386F-09A9-BA78-5543-DFCE2A3A8338" id=
"_5DBC386F-09A9-BA78-5543-DFCE2A3A8338"></a> <a name=
"section-6.6.3" id="section-6.6.3"></a>
<h3><span class="Bold Italics">Impairment of Fertility</span></h3>
<p class="First">Some clinical studies have shown that SSRIs
(including paroxetine) may affect sperm quality during SSRI
treatment, which may affect fertility in some men.</p>
<p>A reduced pregnancy rate was found in reproduction studies in
rats at a dose of paroxetine of 15 mg/kg/day, which is 2.9 times
the MRHD for major depressive disorder, social anxiety disorder,
and GAD or 2.4 times the MRHD for OCD on a mg/m<span class=
"Sup">2</span> basis. Irreversible lesions occurred in the
reproductive tract of male rats after dosing in toxicity studies
for 2 to 52 weeks. These lesions consisted of vacuolation of
epididymal tubular epithelium at 50 mg/kg/day and atrophic changes
in the seminiferous tubules of the testes with arrested
spermatogenesis at 25 mg/kg/day (9.8 and 4.9 times the MRHD for
major depressive disorder, social anxiety disorder, and GAD; 8.2
and 4.1 times the MRHD for OCD and PD on a mg/m<span class=
"Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"_D9E2FC84-14B8-6661-62B6-4369781BBC7D" id=
"_D9E2FC84-14B8-6661-62B6-4369781BBC7D"></a> <a name="section-6.7"
id="section-6.7"></a>
<h2>Pregnancy</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="34077-8"><a name=
"_012E9AA3-D81B-9387-223B-E039E72A501D" id=
"_012E9AA3-D81B-9387-223B-E039E72A501D"></a> <a name=
"section-6.7.1" id="section-6.7.1"></a>
<h3><span class="Bold Italics">Pregnancy Category
D</span><span class="Bold">.</span></h3>
<p class="First">See <span class="Bold"><a href=
"#_32496B99-5D5B-EA6B-A064-AA7FA71F079B">WARNINGS, Usage in
Pregnancy</a></span>: <span class="Bold Italics"><a href=
"#_1E7F55FB-4E9E-CE77-B2B7-B78DB2FDD281">Teratogenic
Effects</a></span> and <span class="Bold Italics"><a href=
"#_799918B4-28CC-8318-A9D2-CE2442B3F37A">Nonteratogenic
Effects</a></span>.</p>
</div>
</div>
<div class="Section" data-sectioncode="34079-4"><a name=
"_980C1CFE-CFDC-9B18-AFA9-748C3DFDF5BE" id=
"_980C1CFE-CFDC-9B18-AFA9-748C3DFDF5BE"></a> <a name="section-6.8"
id="section-6.8"></a>
<h2>Labor and Delivery</h2>
<p class="First">The effect of paroxetine on labor and delivery in
humans is unknown.</p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"_70780842-C467-7CA6-9818-38717469A2E3" id=
"_70780842-C467-7CA6-9818-38717469A2E3"></a> <a name="section-6.9"
id="section-6.9"></a>
<h2>Nursing Mothers</h2>
<p class="First">Like many other drugs, paroxetine is secreted in
human milk, and caution should be exercised when paroxetine is
administered to a nursing woman.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"_EF939498-0657-131F-4224-2C5AFE6FE462" id=
"_EF939498-0657-131F-4224-2C5AFE6FE462"></a> <a name="section-6.10"
id="section-6.10"></a>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in the pediatric
population have not been established (see <span class=
"Bold"><a href="#_8159213C-7EE2-2385-46F4-473276BA8961">BOX
WARNING</a></span> and <span class="Bold"><a href=
"#_7E089633-A458-6945-7A27-A428B2E04B8E">WARNINGS, Clinical
Worsening and Suicide Risk</a></span>). Three placebo-controlled
trials in 752 pediatric patients with MDD have been conducted with
paroxetine, and the data were not sufficient to support a claim for
use in pediatric patients. Anyone considering the use of paroxetine
in a child or adolescent must balance the potential risks with the
clinical need. Decreased appetite and weight loss have been
observed in association with the use of SSRIs. Consequently,
regular monitoring of weight and growth should be performed in
children and adolescents treated with an SSRI such as
paroxetine.</p>
<p>In placebo-controlled clinical trials conducted with pediatric
patients, the following adverse events were reported in at least 2%
of pediatric patients treated with paroxetine and occurred at a
rate at least twice that for pediatric patients receiving placebo:
emotional lability (including self-harm, suicidal thoughts,
attempted suicide, crying, and mood fluctuations), hostility,
decreased appetite, tremor, sweating, hyperkinesia, and
agitation.</p>
<p>Events reported upon discontinuation of treatment with
paroxetine in the pediatric clinical trials that included a taper
phase regimen, which occurred in at least 2% of patients who
received paroxetine and which occurred at a rate at least twice
that of placebo, were: emotional lability (including suicidal
ideation, suicide attempt, mood changes, and tearfulness),
nervousness, dizziness, nausea, and abdominal pain (see
<span class="Bold"><a href=
"#_305DC541-8AB2-7CBF-8D1C-0360CB638700">DOSAGE AND ADMINISTRATION,
Discontinuation of Treatment With Paroxetine</a></span>).</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"_B838E495-9648-8271-E16E-0CE4A832896E" id=
"_B838E495-9648-8271-E16E-0CE4A832896E"></a> <a name="section-6.11"
id="section-6.11"></a>
<h2>Geriatric Use</h2>
<p class="First">SSRIs and SNRIs, including paroxetine, have been
associated with cases of clinically significant hyponatremia in
elderly patients, who may be at greater risk for this adverse event
(see <span class="Bold"><a href=
"#_BE9894E9-F7FB-0FD4-D236-ECBD38C0BCCF">PRECAUTIONS,
Hyponatremia</a></span>).</p>
<p>In worldwide premarketing clinical trials with paroxetine, 17%
of patients treated with paroxetine (approximately 700) were 65
years of age or older. Pharmacokinetic studies revealed a decreased
clearance in the elderly, and a lower starting dose is recommended;
there were, however, no overall differences in the adverse event
profile between elderly and younger patients, and effectiveness was
similar in younger and older patients (see <span class=
"Bold"><a href="#_789222FE-AEEA-626B-45EB-42B78AA26763">CLINICAL
PHARMACOLOGY</a></span> and <span class="Bold"><a href=
"#_CB52CA1B-9E5C-4EE9-409E-70225180C0EB">DOSAGE AND
ADMINISTRATION</a></span>).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="_0A4013DB-7E48-5552-2F7C-B44B4DA4013D" id=
"_0A4013DB-7E48-5552-2F7C-B44B4DA4013D"></a> <a name="section-7"
id="section-7"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_C15C3734-D6DB-2FBB-B800-F313E97F3EE5" id=
"_C15C3734-D6DB-2FBB-B800-F313E97F3EE5"></a> <a name="section-7.1"
id="section-7.1"></a>
<h2>Associated With Discontinuation of Treatment</h2>
<p class="First">Twenty percent (1,199/6,145) of patients treated
with paroxetine in worldwide clinical trials in major depressive
disorder and 16.1% (84/522), 11.8% (64/542), 9.4% (44/469), and
10.7% (79/735) of patients treated with paroxetine in worldwide
trials in social anxiety disorder, OCD, panic disorder, and GAD
respectively, discontinued treatment due to an adverse event. The
most common events (≥ 1%) associated with discontinuation and
considered to be drug related (i.e., those events associated with
dropout at a rate approximately twice or greater for paroxetine
compared to placebo) included the following:</p>
<div class="scrollingtable">
<table frame="box" width="75%">
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center" colspan="2" rowspan="1"><span class="Bold">Major
Depressive Disorder</span></td>
<td align="center" colspan="2" rowspan="1">
<p class="First"><span class="Bold">OCD</span></p>
</td>
<td align="center" colspan="2" rowspan="1">
<p class="First"><span class="Bold">Panic Disorder</span></p>
</td>
<td align="center" colspan="2" rowspan="1">
<p class="First"><span class="Bold">Social Anxiety
Disorder</span></p>
</td>
<td align="center" colspan="2" rowspan="1"><span class=
"Bold">Generalized Anziety Disorder</span></td>
</tr>
<tr>
<td align="left" colspan="1"></td>
<td align="center" colspan="1"><span class=
"Bold">Paroxetine</span></td>
<td align="center" colspan="1"><span class=
"Bold">Placebo</span></td>
<td align="center" colspan="1"><span class=
"Bold">Paroxetine</span></td>
<td align="center" colspan="1"><span class=
"Bold">Placebo</span></td>
<td align="center" colspan="1"><span class=
"Bold">Paroxetine</span></td>
<td align="center" colspan="1"><span class=
"Bold">Placebo</span></td>
<td align="center" colspan="1"><span class=
"Bold">Paroxetine</span></td>
<td align="center" colspan="1"><span class=
"Bold">Placebo</span></td>
<td align="center" colspan="1"><span class=
"Bold">Paroxetine</span></td>
<td align="center" colspan="1"><span class=
"Bold">Placebo</span></td>
</tr>
<tr>
<td align="left" colspan="1"><span class="Bold">CNS</span></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="2" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Somnolence</td>
<td align="center" colspan="1">2.3%</td>
<td align="center" rowspan="1">0.7%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.9%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">3.4%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">2.0%</td>
<td align="center" rowspan="1">0.2%</td>
</tr>
<tr>
<td align="left" colspan="1">Insomnia</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1">—</td>
<td align="center" colspan="1">1.7%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1">1.3%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">3.1%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Agitation</td>
<td align="center" colspan="1">1.1%</td>
<td align="center" rowspan="1">0.5%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Tremor</td>
<td align="center" colspan="1">1.1%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.7%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Anxiety</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1">—</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.1%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Dizziness</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1">—</td>
<td align="center" colspan="1">1.5%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.9%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0.2%</td>
</tr>
<tr>
<td align="left" colspan="1"><span class=
"Bold">Gastrointestinal</span></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Constipation</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.1%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Nausea</td>
<td align="center" colspan="1">3.2%</td>
<td align="center" rowspan="1">1.1%</td>
<td align="center" colspan="1">1.9%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1">3.2%</td>
<td align="center" rowspan="1">1.2%</td>
<td align="center" colspan="1">4.0%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">2.0%</td>
<td align="center" rowspan="1">0.2%</td>
</tr>
<tr>
<td align="left" colspan="1">Diarrhea</td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Dry mouth</td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Vomiting</td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Flatulence</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1"><span class="Bold">Other</span></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1">Asthenia</td>
<td align="center" colspan="1">1.6%</td>
<td align="center" rowspan="1">0.4%</td>
<td align="center" colspan="1">1.9%</td>
<td align="center" rowspan="1">0.4%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">2.5%</td>
<td align="center" rowspan="1">0.6%</td>
<td align="center" colspan="1">1.8%</td>
<td align="center" rowspan="1">0.2%</td>
</tr>
<tr>
<td align="left" colspan="1">Abnormal ejaculation<span class=
"Sup">a</span></td>
<td align="center" colspan="1">1.6%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1">2.1%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">4.9%</td>
<td align="center" rowspan="1">0.6%</td>
<td align="center" colspan="1">2.5%</td>
<td align="center" rowspan="1">0.5%</td>
</tr>
<tr>
<td align="left" colspan="1">Sweating</td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0.3%</td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.1%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1">1.1%</td>
<td align="center" rowspan="1">0.2%</td>
</tr>
<tr>
<td align="left" colspan="1">Impotence<span class=
"Sup">a</span></td>
<td align="center" colspan="1">—</td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.5%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
<tr class="Last">
<td align="left" colspan="1">Libido Decreased</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
<td align="center" colspan="1">1.0%</td>
<td align="center" rowspan="1">0%</td>
<td align="center" colspan="1"></td>
<td align="center" rowspan="1"></td>
</tr>
</tbody>
</table>
</div>
<p class="Footnote">Where numbers are not provided the incidence of
the adverse events in patients treated with paroxetine was not
&gt;1% or was not greater than or equal to 2 times the incidence of
placebo.</p>
<p class="Footnote">a. Incidence corrected for gender.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_BDE55CA0-EC39-64F5-1FE6-97F6B93969A1" id=
"_BDE55CA0-EC39-64F5-1FE6-97F6B93969A1"></a> <a name="section-7.2"
id="section-7.2"></a>
<h2>Commonly Observed Adverse Events</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_E9BDB5A6-5FDA-242D-6276-0607AC04841A" id=
"_E9BDB5A6-5FDA-242D-6276-0607AC04841A"></a> <a name=
"section-7.2.1" id="section-7.2.1"></a>
<h3><span class="Bold Italics">Major Depressive
Disorder</span></h3>
<p class="First">The most commonly observed adverse events
associated with the use of paroxetine (incidence of 5% or greater
and incidence for paroxetine at least twice that for placebo,
derived from Table 2) were: Asthenia, sweating, nausea, decreased
appetite, somnolence, dizziness, insomnia, tremor, nervousness,
ejaculatory disturbance, and other male genital disorders.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_FFEBD668-938E-FC2E-CD2C-12EE6337E5FB" id=
"_FFEBD668-938E-FC2E-CD2C-12EE6337E5FB"></a> <a name=
"section-7.2.2" id="section-7.2.2"></a>
<h3><span class="Bold Italics">Obsessive Compulsive
Disorder</span></h3>
<p class="First">The most commonly observed adverse events
associated with the use of paroxetine (incidence of 5% or greater
and incidence for paroxetine at least twice that of placebo,
derived from Table 3) were: Nausea, dry mouth, decreased appetite,
constipation, dizziness, somnolence, tremor, sweating, impotence,
and abnormal ejaculation.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D21CF269-A3D7-7F64-0948-0139557B11E9" id=
"_D21CF269-A3D7-7F64-0948-0139557B11E9"></a> <a name=
"section-7.2.3" id="section-7.2.3"></a>
<h3><span class="Bold Italics">Panic Disorder</span></h3>
<p class="First">The most commonly observed adverse events
associated with the use of paroxetine (incidence of 5% or greater
and incidence for paroxetine at least twice that for placebo,
derived from Table 3) were: Asthenia, sweating, decreased appetite,
libido decreased, tremor, abnormal ejaculation, female genital
disorders, and impotence.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_DD91E9AD-B1C2-ACEF-53E7-6BD354C84918" id=
"_DD91E9AD-B1C2-ACEF-53E7-6BD354C84918"></a> <a name=
"section-7.2.4" id="section-7.2.4"></a>
<h3><span class="Bold Italics">Social Anxiety Disorder</span></h3>
<p class="First">The most commonly observed adverse events
associated with the use of paroxetine (incidence of 5% or greater
and incidence for paroxetine at least twice that for placebo,
derived from Table 3) were: Sweating, nausea, dry mouth,
constipation, decreased appetite, somnolence, tremor, libido
decreased, yawn, abnormal ejaculation, female genital disorders,
and impotence.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_1370E7A4-ECA4-79C2-F05E-2E8A66DD108A" id=
"_1370E7A4-ECA4-79C2-F05E-2E8A66DD108A"></a> <a name=
"section-7.2.5" id="section-7.2.5"></a>
<h3><span class="Bold Italics">Generalized Anxiety
Disorder</span></h3>
<p class="First">The most commonly observed adverse events
associated with the use of paroxetine (incidence of 5% or greater
and incidence for paroxetine at least twice that for placebo,
derived from Table 4) were: Asthenia, infection, constipation,
decreased appetite, dry mouth, nausea, libido decreased,
somnolence, tremor, sweating, and abnormal ejaculation.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_97909B51-2A71-AEDC-1326-F82B3CAF0AEC" id=
"_97909B51-2A71-AEDC-1326-F82B3CAF0AEC"></a> <a name="section-7.3"
id="section-7.3"></a>
<h2>Incidence in Controlled Clinical Trials</h2>
<p class="First">The prescriber should be aware that the figures in
the tables following cannot be used to predict the incidence of
side effects in the course of usual medical practice where patient
characteristics and other factors differ from those that prevailed
in the clinical trials. Similarly, the cited frequencies cannot be
compared with figures obtained from other clinical investigations
involving different treatments, uses, and investigators. The cited
figures, however, do provide the prescribing physician with some
basis for estimating the relative contribution of drug and nondrug
factors to the side effect incidence rate in the populations
studied.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_B534A655-F63A-9FAA-471E-0A09F1044027" id=
"_B534A655-F63A-9FAA-471E-0A09F1044027"></a> <a name=
"section-7.3.1" id="section-7.3.1"></a>
<h3><span class="Bold Italics">Major Depressive
Disorder</span></h3>
<p class="First">Table 2 enumerates adverse events that occurred at
an incidence of 1% or more among paroxetine-treated patients who
participated in short-term (6-week) placebo-controlled trials in
which patients were dosed in a range of 20 mg to 50 mg/day.
Reported adverse events were classified using a standard
COSTART-based Dictionary terminology.</p>
<div class="scrollingtable">
<table frame="box" width="75%">
<caption><span>Table 2. Treatment-Emergent Adverse Experience
Incidence in Placebo-Controlled Clinical Trials for Major
Depressive Disorder<span class="Sup">a</span></span></caption>
<colgroup>
<col>
<col>
<col>
<col></colgroup>
<thead>
<tr class="First Last">
<td valign="bottom">
<p class="First"><span class="Bold">Body System</span></p>
</td>
<td valign="bottom">
<p class="First"><span class="Bold">Preferred Term</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Paroxetine (n</span>
<span class="Bold">=</span> <span class="Bold">421)</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo (n</span> <span class=
"Bold">=</span> <span class="Bold">421)</span></p>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td valign="top">
<p class="First">Body as a Whole</p>
</td>
<td valign="top">
<p class="First">Headache</p>
</td>
<td align="center" valign="top">
<p class="First">18%</p>
</td>
<td align="center" valign="top">
<p class="First">17%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Asthenia</p>
</td>
<td align="center" valign="top">
<p class="First">15%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Cardiovascular</p>
</td>
<td valign="top">
<p class="First">Palpitation</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Vasodilation</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dermatologic</p>
</td>
<td valign="top">
<p class="First">Sweating</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Rash</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Gastrointestinal</p>
</td>
<td valign="top">
<p class="First">Nausea</p>
</td>
<td align="center" valign="top">
<p class="First">26%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dry Mouth</p>
</td>
<td align="center" valign="top">
<p class="First">18%</p>
</td>
<td align="center" valign="top">
<p class="First">12%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Constipation</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Diarrhea</p>
</td>
<td align="center" valign="top">
<p class="First">12%</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Decreased Appetite</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Flatulence</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Oropharynx Disorder<span class="Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dyspepsia</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Musculoskeletal</p>
</td>
<td valign="top">
<p class="First">Myopathy</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Myalgia</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Myasthenia</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Nervous System</p>
</td>
<td valign="top">
<p class="First">Somnolence</p>
</td>
<td align="center" valign="top">
<p class="First">23%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dizziness</p>
</td>
<td align="center" valign="top">
<p class="First">13%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Insomnia</p>
</td>
<td align="center" valign="top">
<p class="First">13%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Tremor</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Nervousness</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Anxiety</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Paresthesia</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Libido Decreased</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Drugged Feeling</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Confusion</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Respiration</p>
</td>
<td valign="top">
<p class="First">Yawn</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Special Senses</p>
</td>
<td valign="top">
<p class="First">Blurred Vision</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Taste Perversion</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Urogenital System</p>
</td>
<td valign="top">
<p class="First">Ejaculatory Disturbance<span class=
"Sup">c,d</span></p>
</td>
<td align="center" valign="top">
<p class="First">13%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First"></p>
</td>
<td valign="top">
<p class="First">Other Male Genital Disorders<span class=
"Sup">c,e</span></p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Urinary Frequency</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Urination Disorder<span class="Sup">f</span></p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
<tr class="Last">
<td valign="top"></td>
<td valign="top">
<p class="First">Female Genital Disorders<span class=
"Sup">c,g</span></p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
</tr>
</tbody>
</table>
</div>
<p class="Footnote">a. Events reported by at least 1% of patients
treated with paroxetine are included, except the following events
which had an incidence on placebo ≥ paroxetine: Abdominal pain,
agitation, back pain, chest pain, CNS stimulation, fever, increased
appetite, myoclonus, pharyngitis, postural hypotension, respiratory
disorder (includes mostly “cold symptoms” or “URI”), trauma, and
vomiting.</p>
<p class="Footnote">b. Includes mostly “lump in throat” and
“tightness in throat.”</p>
<p class="Footnote">c. Percentage corrected for gender.</p>
<p class="Footnote">d. Mostly “ejaculatory delay.”</p>
<p class="Footnote">e. Includes “anorgasmia,” “erectile
difficulties,” “delayed ejaculation/orgasm,” and “sexual
dysfunction,” and “impotence.”</p>
<p class="Footnote">f. Includes mostly “difficulty with
micturition” and “urinary hesitancy.”</p>
<p class="Footnote">g. Includes mostly “anorgasmia” and “difficulty
reaching climax/orgasm.”</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_A9D02B29-9E88-9F69-85D2-1E495BFC6CC1" id=
"_A9D02B29-9E88-9F69-85D2-1E495BFC6CC1"></a> <a name=
"section-7.3.2" id="section-7.3.2"></a>
<h3><span class="Bold Italics">Obsessive Compulsive Disorder, Panic
Disorder, and Social Anxiety Disorder</span></h3>
<p class="First">Table 3 enumerates adverse events that occurred at
a frequency of 2% or more among OCD patients on paroxetine who
participated in placebo-controlled trials of 12-weeks duration in
which patients were dosed in a range of 20 mg to 60 mg/day or among
patients with panic disorder on paroxetine who participated in
placebo-controlled trials of 10- to 12-weeks duration in which
patients were dosed in a range of 10 mg to 60 mg/day or among
patients with social anxiety disorder on paroxetine who
participated in placebo-controlled trials of 12-weeks duration in
which patients were dosed in a range of 20 mg to 50 mg/day.</p>
<div class="scrollingtable">
<table frame="box">
<caption><span>Table 3. Treatment-Emergent Adverse Experience
Incidence in Placebo-Controlled Clinical Trials for Obsessive
Compulsive Disorder, Panic Disorder, and Social Anxiety
Disorder<span class="Sup">a</span></span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col></colgroup>
<thead>
<tr class="First Last">
<td valign="bottom">
<p class="First"><span class="Bold">Body System</span></p>
</td>
<td valign="bottom">
<p class="First"><span class="Bold">Preferred Term</span></p>
</td>
<td align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Obsessive Compulsive
Disorder</span></p>
</td>
<td align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Panic Disorder</span></p>
</td>
<td align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Social Anxiety
Disorder</span></p>
</td>
</tr>
</thead>
<tbody align="left" valign="top">
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Paroxetine</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Paroxetine</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Paroxetine</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Placezbo</span></p>
</td>
</tr>
<tr>
<td colspan="1" valign="top"></td>
<td colspan="1" valign="top"></td>
<td align="center" colspan="1" valign="top">
<p class="First"><span class="Bold">(n</span><span class=
"Bold">=</span> <span class="Bold">542)</span></p>
</td>
<td align="center" colspan="1" valign="top"><span class=
"Bold">(n</span><span class="Bold">=</span> <span class=
"Bold">265)</span></td>
<td align="center" colspan="1" valign="top"><span class=
"Bold">(n</span><span class="Bold">=</span> <span class=
"Bold">469)</span></td>
<td align="center" colspan="1" valign="top"><span class=
"Bold">(n</span><span class="Bold">=</span> <span class=
"Bold">324)</span></td>
<td align="center" colspan="1" valign="top"><span class=
"Bold">(n</span><span class="Bold">=</span> <span class=
"Bold">425)</span></td>
<td align="center" colspan="1" valign="top"><span class=
"Bold">(n=339)</span></td>
</tr>
<tr>
<td valign="top">
<p class="First">Body as a Whole</p>
</td>
<td valign="top">
<p class="First">Asthenia</p>
</td>
<td align="center" valign="top">
<p class="First">22%</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">22%</p>
</td>
<td align="right" valign="top">
<p class="Center First">14%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Abdominal Pain</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Chest Pain</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Back Pain</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Chills</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Trauma</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Cardiovascular</p>
</td>
<td valign="top">
<p class="First">Vasodilation</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Palpitation</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dermatologic</p>
</td>
<td valign="top">
<p class="First">Sweating</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Rash</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Gastrointestinal</p>
</td>
<td valign="top">
<p class="First">Nausea</p>
</td>
<td align="center" valign="top">
<p class="First">23%</p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">23%</p>
</td>
<td align="center" valign="top">
<p class="First">17%</p>
</td>
<td align="center" valign="top">
<p class="First">25%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dry Mouth</p>
</td>
<td align="center" valign="top">
<p class="First">18%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">18%</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Constipation</p>
</td>
<td align="center" valign="top">
<p class="First">16%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Diarrhea</p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">12%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Decreased Appetite</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dyspepsia</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Flatulence</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Increased Appetite</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Vomiting</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Musculoskeletal</p>
</td>
<td valign="top">
<p class="First">Myalgia</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Nervous System</p>
</td>
<td valign="top">
<p class="First">Insomnia</p>
</td>
<td align="center" valign="top">
<p class="First">24%</p>
</td>
<td align="center" valign="top">
<p class="First">13%</p>
</td>
<td align="center" valign="top">
<p class="First">18%</p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">21%</p>
</td>
<td align="center" valign="top">
<p class="First">16%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Somnolence</p>
</td>
<td align="center" valign="top">
<p class="First">24%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
<td align="center" valign="top">
<p class="First">19%</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">22%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dizziness</p>
</td>
<td align="center" valign="top">
<p class="First">12%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Tremor</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Nervousness</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Libido Decreased</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">12%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Agitation</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Anxiety</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Abnormal Dreams</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Concentration Impaired</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Depersonalization</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Myoclonus</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Amnesia</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Respiratory System</p>
</td>
<td valign="top">
<p class="First">Rhinitis</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Pharyngitis</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Yawn</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Special Senses</p>
</td>
<td valign="top">
<p class="First">Abnormal Vision</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Taste Perversion</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Urogenital System</p>
</td>
<td valign="top">
<p class="First">Abnormal Ejaculation<span class="Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">23%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">21%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">28%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Dysmenorrhea</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Female Genital Disorder<span class=
"Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Impotence<span class="Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Urinary Frequency</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top">
<p class="First">Urination Impaired</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">0%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr class="Last">
<td valign="top"></td>
<td valign="top">
<p class="First">Urinary Tract Infection</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
</tbody>
</table>
</div>
<p class="Footnote">a. Events reported by at least 2% of OCD, panic
disorder, and social anxiety disorder in patients treated with
paroxetine are included, except the following events which had an
incidence on placebo ≥ paroxetine: [OCD]: Abdominal pain,
agitation, anxiety, back pain, cough increased, depression,
headache, hyperkinesia, infection, paresthesia, pharyngitis,
respiratory disorder, rhinitis, and sinusitis. [panic disorder]:
Abnormal dreams, abnormal vision, chest pain, cough increased,
depersonalization, depression, dysmenorrhea, dyspepsia, flu
syndrome, headache, infection, myalgia, nervousness, palpitation,
paresthesia, pharyngitis, rash, respiratory disorder, sinusitis,
taste perversion, trauma, urination impaired, and vasodilation.
[social anxiety disorder]: Abdominal pain, depression, headache,
infection, respiratory disorder, and sinusitis.</p>
<p class="Footnote">b. Percentage corrected for gender.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_E3CC43E7-4997-C91D-C016-EFC82B447C0F" id=
"_E3CC43E7-4997-C91D-C016-EFC82B447C0F"></a> <a name=
"section-7.3.3" id="section-7.3.3"></a>
<h3><span class="Bold Italics">Generalized Anxiety
Disorder</span></h3>
<p class="First">Table 4 enumerates adverse events that occurred at
a frequency of 2% or more among GAD patients on paroxetine who
participated in placebo-controlled trials of 8-weeks duration in
which patients were dosed in a range of 10 mg/day to 50 mg/day</p>
<div class="scrollingtable">
<table frame="box">
<caption><span>Table 4. Treatment-Emergent Adverse Experience
Incidence in Placebo-Controlled Clinical Trials for Generalized
Anxiety Disorder<span class="Sup">a</span></span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col></colgroup>
<thead>
<tr class="First Last">
<td valign="bottom">
<p class="First"><span class="Bold">Body System</span></p>
</td>
<td valign="bottom">
<p class="First"><span class="Bold">Preferred Term</span></p>
</td>
<td colspan="2" valign="bottom">
<p class="First"><span class="Bold">Generalized Anxiety
Disorder</span></p>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td valign="top"></td>
<td valign="top"></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Paroxetine (n</span>
<span class="Bold">=</span> <span class="Bold">735)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Placebo (n</span> <span class=
"Bold">=</span> <span class="Bold">529)</span></p>
</td>
</tr>
<tr>
<td rowspan="5" valign="top">
<p class="First">Body as a Whole</p>
</td>
<td valign="top">
<p class="First">Asthenia</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Headache</p>
</td>
<td align="center" valign="top">
<p class="First">17%</p>
</td>
<td align="center" valign="top">
<p class="First">14%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Infection</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Abdominal Pain</p>
</td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top">
<p class="First">Trauma</p>
</td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top">
<p class="First">Cardiovascular</p>
</td>
<td valign="top">
<p class="First">Vasodilation</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dermatologic</p>
</td>
<td valign="top">
<p class="First">Sweating</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td rowspan="7" valign="top">
<p class="First">Gastrointestinal</p>
</td>
<td valign="top">
<p class="First">Nausea</p>
</td>
<td align="center" valign="top">
<p class="First">20%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dry Mouth</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Constipation</p>
</td>
<td align="center" valign="top">
<p class="First">10%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Diarrhea</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Decreased Appetite</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Vomiting</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dyspepsia</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td rowspan="7" valign="top">
<p class="First">Nervous System</p>
</td>
<td valign="top">
<p class="First">Insomnia</p>
</td>
<td align="center" valign="top">
<p class="First">11%</p>
</td>
<td align="center" valign="top">
<p class="First">8%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Somnolence</p>
</td>
<td align="center" valign="top">
<p class="First">15%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dizziness</p>
</td>
<td align="center" valign="top">
<p class="First">6%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Tremor</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Nervousness</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Libido Decreased</p>
</td>
<td align="center" valign="top">
<p class="First">9%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Abnormal Dreams</p>
</td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td rowspan="3" valign="top">
<p class="First">Respiratory System</p>
</td>
<td valign="top">
<p class="First">Respiratory Disorder</p>
</td>
<td align="center" valign="top">
<p class="First">7%</p>
</td>
<td align="center" valign="top">
<p class="First">5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Sinusitis</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Yawn</p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">—</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Special Senses</p>
</td>
<td valign="top">
<p class="First">Abnormal Vision</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr>
<td rowspan="3" valign="top">
<p class="First">Urogenital System</p>
</td>
<td valign="top">
<p class="First">Abnormal Ejaculation<span class="Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">25%</p>
</td>
<td align="center" valign="top">
<p class="First">2%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Female Genital Disorder<span class=
"Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">1%</p>
</td>
</tr>
<tr class="Last">
<td valign="top">
<p class="First">Impotence<span class="Sup">b</span></p>
</td>
<td align="center" valign="top">
<p class="First">4%</p>
</td>
<td align="center" valign="top">
<p class="First">3%</p>
</td>
</tr>
</tbody>
</table>
</div>
<p class="Footnote">a. Events reported by at least 2% of GAD in
patients treated with paroxetine are included, except the following
events which had an incidence on placebo ≥ paroxetine [GAD]:
Abdominal pain, back pain, trauma, dyspepsia, myalgia, and
pharyngitis.</p>
<p class="Footnote">b. Percentage corrected for gender.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_DFDD33AC-DC0F-E130-F51D-7017BDA350C1" id=
"_DFDD33AC-DC0F-E130-F51D-7017BDA350C1"></a> <a name=
"section-7.3.4" id="section-7.3.4"></a>
<h3><span class="Bold Italics">Dose Dependency of Adverse
Events</span></h3>
<p class="First">A comparison of adverse event rates in a
fixed-dose study comparing 10, 20, 30, and 40 mg/day of paroxetine
with placebo in the treatment of major depressive disorder revealed
a clear dose dependency for some of the more common adverse events
associated with use of paroxetine, as shown in Table 5:</p>
<div class="scrollingtable">
<table frame="box">
<caption><span>Table 5. Treatment-Emergent Adverse Experience
Incidence in a Dose-Comparison Trial in the Treatment of Major
Depressive Disorder<span class="Sup">a</span></span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col></colgroup>
<thead>
<tr class="First">
<td rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Body System/Preferred
Term</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo</span></p>
</td>
<td align="center" colspan="4" valign="bottom">
<p class="First"><span class="Bold">Paroxetine</span></p>
</td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">
<p class="First"><span class="Bold">n</span> <span class=
"Bold">=</span> <span class="Bold">51</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">10 mg n</span> <span class=
"Bold">=</span> <span class="Bold">102</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">20 mg n</span> <span class=
"Bold">=</span> <span class="Bold">104</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">30 mg n</span> <span class=
"Bold">=</span> <span class="Bold">101</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">40 mg n</span> <span class=
"Bold">=</span> <span class="Bold">102</span></p>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td valign="top">
<p class="First"><span class="Bold">Body as a Whole</span></p>
</td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Asthenia</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">2.9%</p>
</td>
<td align="center" valign="top">
<p class="First">10.6%</p>
</td>
<td align="center" valign="top">
<p class="First">13.9%</p>
</td>
<td align="center" valign="top">
<p class="First">12.7%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First"><span class="Bold">Dermatology</span></p>
</td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Sweating</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">1.0%</p>
</td>
<td align="center" valign="top">
<p class="First">6.7%</p>
</td>
<td align="center" valign="top">
<p class="First">8.9%</p>
</td>
<td align="center" valign="top">
<p class="First">11.8%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First"><span class="Bold">Gastrointestinal</span></p>
</td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Constipation</p>
</td>
<td align="center" valign="top">
<p class="First">5.9%</p>
</td>
<td align="center" valign="top">
<p class="First">4.9%</p>
</td>
<td align="center" valign="top">
<p class="First">7.7%</p>
</td>
<td align="center" valign="top">
<p class="First">9.9%</p>
</td>
<td align="center" valign="top">
<p class="First">12.7%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Decreased Appetite</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">5.8%</p>
</td>
<td align="center" valign="top">
<p class="First">4.0%</p>
</td>
<td align="center" valign="top">
<p class="First">4.9%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Diarrhea</p>
</td>
<td align="center" valign="top">
<p class="First">7.8%</p>
</td>
<td align="center" valign="top">
<p class="First">9.8%</p>
</td>
<td align="center" valign="top">
<p class="First">19.2%</p>
</td>
<td align="center" valign="top">
<p class="First">7.9%</p>
</td>
<td align="center" valign="top">
<p class="First">14.7%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Dry Mouth</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">10.8%</p>
</td>
<td align="center" valign="top">
<p class="First">18.3%</p>
</td>
<td align="center" valign="top">
<p class="First">15.8%</p>
</td>
<td align="center" valign="top">
<p class="First">20.6%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Nausea</p>
</td>
<td align="center" valign="top">
<p class="First">13.7%</p>
</td>
<td align="center" valign="top">
<p class="First">14.7%</p>
</td>
<td align="center" valign="top">
<p class="First">26.9%</p>
</td>
<td align="center" valign="top">
<p class="First">34.7%</p>
</td>
<td align="center" valign="top">
<p class="First">36.3%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First"><span class="Bold">Nervous System</span></p>
</td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Anxiety</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">5.8%</p>
</td>
<td align="center" valign="top">
<p class="First">5.9%</p>
</td>
<td align="center" valign="top">
<p class="First">5.9%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Dizziness</p>
</td>
<td align="center" valign="top">
<p class="First">3.9%</p>
</td>
<td align="center" valign="top">
<p class="First">6.9%</p>
</td>
<td align="center" valign="top">
<p class="First">6.7%</p>
</td>
<td align="center" valign="top">
<p class="First">8.9%</p>
</td>
<td align="center" valign="top">
<p class="First">12.7%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Nervousness</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">5.9%</p>
</td>
<td align="center" valign="top">
<p class="First">5.8%</p>
</td>
<td align="center" valign="top">
<p class="First">4.0%</p>
</td>
<td align="center" valign="top">
<p class="First">2.9%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Paresthesia</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">2.9%</p>
</td>
<td align="center" valign="top">
<p class="First">1.0%</p>
</td>
<td align="center" valign="top">
<p class="First">5.0%</p>
</td>
<td align="center" valign="top">
<p class="First">5.9%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Somnolence</p>
</td>
<td align="center" valign="top">
<p class="First">7.8%</p>
</td>
<td align="center" valign="top">
<p class="First">12.7%</p>
</td>
<td align="center" valign="top">
<p class="First">18.3%</p>
</td>
<td align="center" valign="top">
<p class="First">20.8%</p>
</td>
<td align="center" valign="top">
<p class="First">21.6%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Tremor</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">7.7%</p>
</td>
<td align="center" valign="top">
<p class="First">7.9%</p>
</td>
<td align="center" valign="top">
<p class="First">14.7%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First"><span class="Bold">Special Senses</span></p>
</td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Blurred Vision</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">2.9%</p>
</td>
<td align="center" valign="top">
<p class="First">2.9%</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
<td align="center" valign="top">
<p class="First">7.8%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First"><span class="Bold">Urogenital System</span></p>
</td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Abnormal Ejaculation</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">5.8%</p>
</td>
<td align="center" valign="top">
<p class="First">6.5%</p>
</td>
<td align="center" valign="top">
<p class="First">10.6%</p>
</td>
<td align="center" valign="top">
<p class="First">13.0%</p>
</td>
</tr>
<tr>
<td align="justify" valign="top">
<p class="First">Impotence</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">1.9%</p>
</td>
<td align="center" valign="top">
<p class="First">4.3%</p>
</td>
<td align="center" valign="top">
<p class="First">6.4%</p>
</td>
<td align="center" valign="top">
<p class="First">1.9%</p>
</td>
</tr>
<tr class="Last">
<td valign="top">
<p class="First">Male Genital Disorders</p>
</td>
<td align="center" valign="top">
<p class="First">0.0%</p>
</td>
<td align="center" valign="top">
<p class="First">3.8%</p>
</td>
<td align="center" valign="top">
<p class="First">8.7%</p>
</td>
<td align="center" valign="top">
<p class="First">6.4%</p>
</td>
<td align="center" valign="top">
<p class="First">3.7%</p>
</td>
</tr>
</tbody>
</table>
</div>
<p class="Footnote"><span class="Sup">a</span> Rule for including
adverse events in table: Incidence at least 5% for 1 of paroxetine
groups and ≥ twice the placebo incidence for at least 1 paroxetine
group.</p>
<p>In a fixed-dose study comparing placebo and 20, 40, and 60 mg of
paroxetine in the treatment of OCD, there was no clear relationship
between adverse events and the dose of paroxetine to which patients
were assigned. No new adverse events were observed in the group
treated with 60 mg of paroxetine compared to any of the other
treatment groups.</p>
<p>In a fixed-dose study comparing placebo and 10, 20, and 40 mg of
paroxetine in the treatment of panic disorder, there was no clear
relationship between adverse events and the dose of paroxetine to
which patients were assigned, except for asthenia, dry mouth,
anxiety, libido decreased, tremor, and abnormal ejaculation. In
flexible-dose studies, no new adverse events were observed in
patients receiving 60 mg of paroxetine compared to any of the other
treatment groups.</p>
<p>In a fixed-dose study comparing placebo and 20, 40, and 60 mg of
paroxetine in the treatment of social anxiety disorder, for most of
the adverse events, there was no clear relationship between adverse
events and the dose of paroxetine to which patients were
assigned.</p>
<p>In a fixed-dose study comparing placebo and 20 and 40 mg of
paroxetine in the treatment of generalized anxiety disorder, for
most of the adverse events, there was no clear relationship between
adverse events and the dose of paroxetine to which patients were
assigned, except for the following adverse events: Asthenia,
constipation, and abnormal ejaculation.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_ABFFF1B2-13B1-16FC-E8DF-8CC47CDB76F8" id=
"_ABFFF1B2-13B1-16FC-E8DF-8CC47CDB76F8"></a> <a name=
"section-7.3.5" id="section-7.3.5"></a>
<h3><span class="Bold Italics">Adaptation to Certain Adverse
Events</span></h3>
<p class="First">Over a 4- to 6-week period, there was evidence of
adaptation to some adverse events with continued therapy (e.g.,
nausea and dizziness), but less to other effects (e.g., dry mouth,
somnolence, and asthenia).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_253910FA-994F-04DC-3993-D56A23159163" id=
"_253910FA-994F-04DC-3993-D56A23159163"></a> <a name=
"section-7.3.6" id="section-7.3.6"></a>
<h3><span class="Bold Italics">Male and Female Sexual Dysfunction
With SSRIs</span></h3>
<p class="First">Although changes in sexual desire, sexual
performance, and sexual satisfaction often occur as manifestations
of a psychiatric disorder, they may also be a consequence of
pharmacologic treatment. In particular, some evidence suggests that
selective serotonin reuptake inhibitors (SSRIs) can cause such
untoward sexual experiences.</p>
<p>Reliable estimates of the incidence and severity of untoward
experiences involving sexual desire, performance, and satisfaction
are difficult to obtain, however, in part because patients and
physicians may be reluctant to discuss them. Accordingly, estimates
of the incidence of untoward sexual experience and performance
cited in product labeling, are likely to underestimate their actual
incidence.</p>
<p>In placebo-controlled clinical trials involving more than 3,200
patients, the ranges for the reported incidence of sexual side
effects in males and females with major depressive disorder, OCD,
panic disorder, social anxiety disorder, and GAD are displayed in
Table 6.</p>
<div class="scrollingtable">
<table frame="box">
<caption><span>Table 6. Incidence of Sexual Adverse Events in
Controlled Clinical Trials</span></caption>
<colgroup>
<col>
<col>
<col></colgroup>
<thead>
<tr class="First Last">
<td valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Paroxetine</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo</span></p>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td valign="top">
<p class="First"><span class="Bold">n (males)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">1446</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">1042</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Decreased Libido</p>
</td>
<td align="center" valign="top">
<p class="First">6 to15%</p>
</td>
<td align="center" valign="top">
<p class="First">0 to 5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Ejaculatory Disturbance</p>
</td>
<td align="center" valign="top">
<p class="First">13 to 28%</p>
</td>
<td align="center" valign="top">
<p class="First">0 to -2%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Impotence</p>
</td>
<td align="center" valign="top">
<p class="First">2 to 9%</p>
</td>
<td align="center" valign="top">
<p class="First">0 to 3%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First"><span class="Bold">n (females)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">1822</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">1340</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Decreased Libido</p>
</td>
<td align="center" valign="top">
<p class="First">0 to 9%</p>
</td>
<td align="center" valign="top">
<p class="First">0 to 2%</p>
</td>
</tr>
<tr class="Last">
<td valign="top">
<p class="First">Orgasmic Disturbance</p>
</td>
<td align="center" valign="top">
<p class="First">2 to 9%</p>
</td>
<td align="center" valign="top">
<p class="First">0 to 1%</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>There are no adequate and well-controlled studies examining
sexual dysfunction with paroxetine treatment.</p>
<p>Paroxetine treatment has been associated with several cases of
priapism. In those cases with a known outcome, patients recovered
without sequelae.</p>
<p>While it is difficult to know the precise risk of sexual
dysfunction associated with the use of SSRIs, physicians should
routinely inquire about such possible side effects.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_35A68BAD-28E0-2402-DF38-EB7AB5D189A6" id=
"_35A68BAD-28E0-2402-DF38-EB7AB5D189A6"></a> <a name=
"section-7.3.7" id="section-7.3.7"></a>
<h3><span class="Bold Italics">Weight and Vital Sign
Changes</span></h3>
<p class="First">Significant weight loss may be an undesirable
result of treatment with paroxetine for some patients but, on
average, patients in controlled trials had minimal (about 1 pound)
weight loss versus smaller changes on placebo and active control.
No significant changes in vital signs (systolic and diastolic blood
pressure, pulse and temperature) were observed in patients treated
with paroxetine in controlled clinical trials.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_F0147035-FBB1-9F37-E7B9-637DD073EE27" id=
"_F0147035-FBB1-9F37-E7B9-637DD073EE27"></a> <a name=
"section-7.3.8" id="section-7.3.8"></a>
<h3><span class="Bold Italics">ECG Changes</span></h3>
<p class="First">In an analysis of ECGs obtained in 682 patients
treated with paroxetine and 415 patients treated with placebo in
controlled clinical trials, no clinically significant changes were
seen in the ECGs of either group.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9C72C2E5-1E41-A56E-13EA-429ABE4AD15A" id=
"_9C72C2E5-1E41-A56E-13EA-429ABE4AD15A"></a> <a name=
"section-7.3.9" id="section-7.3.9"></a>
<h3><span class="Bold Italics">Liver Function Tests</span></h3>
<p class="First">In placebo-controlled clinical trials, patients
treated with paroxetine exhibited abnormal values on liver function
tests at no greater rate than that seen in placebo-treated
patients. In particular, the paroxetine-versus-placebo comparisons
for alkaline phosphatase, SGOT, SGPT, and bilirubin revealed no
differences in the percentage of patients with marked
abnormalities.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_AA3BF946-C447-7769-B4F2-52F74D968EDF" id=
"_AA3BF946-C447-7769-B4F2-52F74D968EDF"></a> <a name=
"section-7.3.10" id="section-7.3.10"></a>
<h3><span class="Bold Italics">Hallucinations</span></h3>
<p class="First">In pooled clinical trials of immediate-release
paroxetine hydrochloride, hallucinations were observed in 22 of
9089 patients receiving drug and 4 of 3187 patients receiving
placebo.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_38B89960-80B7-8471-98C2-28E7BC66103F" id=
"_38B89960-80B7-8471-98C2-28E7BC66103F"></a> <a name="section-7.4"
id="section-7.4"></a>
<h2>Other Events Observed During the Premarketing Evaluation of
Paroxetine</h2>
<p class="First">During its premarketing assessment in major
depressive disorder, multiple doses of paroxetine were administered
to 6,145 patients in phase 2 and 3 studies. The conditions and
duration of exposure to paroxetine varied greatly and included (in
overlapping categories) open and double-blind studies, uncontrolled
and controlled studies, inpatient and outpatient studies, and
fixed-dose, and titration studies. During premarketing clinical
trials in OCD, panic disorder, social anxiety disorder, and
generalized anxiety disorder, 542, 469, 522, and 735 patients,
respectively, received multiple doses of paroxetine. Untoward
events associated with this exposure were recorded by clinical
investigators using terminology of their own choosing.
Consequently, it is not possible to provide a meaningful estimate
of the proportion of individuals experiencing adverse events
without first grouping similar types of untoward events into a
smaller number of standardized event categories.</p>
<p>In the tabulations that follow, reported adverse events were
classified using a standard COSTART-based Dictionary terminology.
The frequencies presented, therefore, represent the proportion of
the 9,089 patients exposed to multiple doses of paroxetine who
experienced an event of the type cited on at least 1 occasion while
receiving paroxetine. All reported events are included except those
already listed in Tables 2 to 5, those reported in terms so general
as to be uninformative and those events where a drug cause was
remote. It is important to emphasize that although the events
reported occurred during treatment with paroxetine, they were not
necessarily caused by it.</p>
<p>Events are further categorized by body system and listed in
order of decreasing frequency according to the following
definitions: Frequent adverse events are those occurring on 1 or
more occasions in at least 1/100 patients (only those not already
listed in the tabulated results from placebo-controlled trials
appear in this listing); infrequent adverse events are those
occurring in 1/100 to 1/1,000 patients; rare events are those
occurring in fewer than 1/1,000 patients. Events of major clinical
importance are also described in the <span class="Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS</a></span>
section.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_421407EB-382D-48B1-2616-DFCF4E3909AA" id=
"_421407EB-382D-48B1-2616-DFCF4E3909AA"></a> <a name=
"section-7.4.1" id="section-7.4.1"></a>
<h3><span class="Bold Italics">Body as a Whole</span></h3>
<p class="First"><span class="Italics">Infrequent:</span> Allergic
reaction, chills, face edema, malaise, neck pain; <span class=
"Italics">rare:</span> Adrenergic syndrome, cellulitis, moniliasis,
neck rigidity, pelvic pain, peritonitis, sepsis, ulcer.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_526F914D-0858-389E-B55A-08C1F8DAF7E0" id=
"_526F914D-0858-389E-B55A-08C1F8DAF7E0"></a> <a name=
"section-7.4.2" id="section-7.4.2"></a>
<h3><span class="Bold Italics">Cardiovascular System</span></h3>
<p class="First"><span class="Italics">Frequent:</span>
Hypertension, tachycardia; <span class="Italics">infrequent:</span>
Bradycardia, hematoma, hypotension, migraine, postural hypotension,
syncope; <span class="Italics">rare:</span> Angina pectoris,
arrhythmia nodal, atrial fibrillation, bundle branch block,
cerebral ischemia, cerebrovascular accident, congestive heart
failure, heart block, low cardiac output, myocardial infarct,
myocardial ischemia, pallor, phlebitis, pulmonary embolus,
supraventricular extrasystoles, thrombophlebitis, thrombosis,
varicose vein, vascular headache, ventricular extrasystoles.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_EE12E027-875D-34EA-F9E9-C2C7DFC9E295" id=
"_EE12E027-875D-34EA-F9E9-C2C7DFC9E295"></a> <a name=
"section-7.4.3" id="section-7.4.3"></a>
<h3><span class="Bold Italics">Digestive System</span></h3>
<p class="First"><span class="Italics">Infrequent:</span> Bruxism,
colitis, dysphagia, eructation, gastritis, gastroenteritis,
gingivitis, glossitis, increased salivation, liver function tests
abnormal, rectal hemorrhage, ulcerative stomatitis; <span class=
"Italics">rare:</span> Aphthous stomatitis, bloody diarrhea,
bulimia, cardiospasm, cholelithiasis, duodenitis, enteritis,
esophagitis, fecal impactions, fecal incontinence, gum hemorrhage,
hematemesis, hepatitis, ileitis, ileus, intestinal obstruction,
jaundice, melena, mouth ulceration, peptic ulcer, salivary gland
enlargement, sialadenitis, stomach ulcer, stomatitis, tongue
discoloration, tongue edema, tooth caries.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_3B797EC0-428D-48E1-27B4-0AC422CBAA3A" id=
"_3B797EC0-428D-48E1-27B4-0AC422CBAA3A"></a> <a name=
"section-7.4.4" id="section-7.4.4"></a>
<h3><span class="Bold Italics">Endocrine System</span></h3>
<p class="First"><span class="Italics">Rare:</span> Diabetes
mellitus, goiter, hyperthyroidism, hypothyroidism, thyroiditis.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_36415E4E-490E-02AF-066E-65A83BACCCCE" id=
"_36415E4E-490E-02AF-066E-65A83BACCCCE"></a> <a name=
"section-7.4.5" id="section-7.4.5"></a>
<h3><span class="Bold Italics">Hemic and Lymphatic
Systems</span></h3>
<p class="First"><span class="Italics">Infrequent:</span> Anemia,
leukopenia, lymphadenopathy, purpura; <span class=
"Italics">rare:</span> Abnormal erythrocytes, basophilia, bleeding
time increased, eosinophilia, hypochromic anemia, iron deficiency
anemia, leukocytosis, lymphedema, abnormal lymphocytes,
lymphocytosis, microcytic anemia, monocytosis, normocytic anemia,
thrombocythemia, thrombocytopenia.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9132C019-A14A-8C4B-8C5C-7F251D230B5B" id=
"_9132C019-A14A-8C4B-8C5C-7F251D230B5B"></a> <a name=
"section-7.4.6" id="section-7.4.6"></a>
<h3><span class="Bold Italics">Metabolic and
Nutritional</span></h3>
<p class="First"><span class="Italics">Frequent:</span> Weight
gain; <span class="Italics">infrequent:</span> Edema, peripheral
edema, SGOT increased, SGPT increased, thirst, weight loss;
<span class="Italics">rare:</span> Alkaline phosphatase increased,
bilirubinemia, BUN increased, creatinine phosphokinase increased,
dehydration, gamma globulins increased, gout, hypercalcemia,
hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia,
hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, ketosis,
lactic dehydrogenase increased, non-protein nitrogen (NPN)
increased.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_8855323E-06FB-712E-77E6-D39475E38F88" id=
"_8855323E-06FB-712E-77E6-D39475E38F88"></a> <a name=
"section-7.4.7" id="section-7.4.7"></a>
<h3><span class="Bold Italics">Musculoskeletal System</span></h3>
<p class="First"><span class="Italics">Frequent:</span> Arthralgia;
<span class="Italics">infrequent:</span> Arthritis, arthrosis;
<span class="Italics">rare:</span> Bursitis, myositis,
osteoporosis, generalized spasm, tenosynovitis, tetany.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9117724F-4B2B-9601-B06D-0A1B274F8624" id=
"_9117724F-4B2B-9601-B06D-0A1B274F8624"></a> <a name=
"section-7.4.8" id="section-7.4.8"></a>
<h3><span class="Bold Italics">Nervous System</span></h3>
<p class="First"><span class="Italics">Frequent:</span> Emotional
lability, vertigo; <span class="Italics">infrequent:</span>
Abnormal thinking, alcohol abuse, ataxia, dystonia, dyskinesia,
euphoria, hallucinations, hostility, hypertonia, hypesthesia,
hypokinesia, incoordination, lack of emotion, libido increased,
manic reaction, neurosis, paralysis, paranoid reaction;
<span class="Italics">rare:</span> Abnormal gait, akinesia,
antisocial reaction, aphasia, choreoathetosis, circumoral
paresthesias, convulsion, delirium, delusions, diplopia, drug
dependence, dysarthria, extrapyramidal syndrome, fasciculations,
grand mal convulsion, hyperalgesia, hysteria, manic-depressive
reaction, meningitis, myelitis, neuralgia, neuropathy, nystagmus,
peripheral neuritis, psychotic depression, psychosis, reflexes
decreased, reflexes increased, stupor, torticollis, trismus,
withdrawal syndrome.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_E049DD30-F637-97A4-0FE3-649A11E2D6B2" id=
"_E049DD30-F637-97A4-0FE3-649A11E2D6B2"></a> <a name=
"section-7.4.9" id="section-7.4.9"></a>
<h3><span class="Bold Italics">Respiratory System</span></h3>
<p class="First"><span class="Italics">Infrequent:</span> Asthma,
bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia,
respiratory flu; <span class="Italics">rare:</span> Emphysema,
hemoptysis, hiccups, lung fibrosis, pulmonary edema, sputum
increased, stridor, voice alteration.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_F5DD69A5-95B8-3DC5-DBFF-41CA92855826" id=
"_F5DD69A5-95B8-3DC5-DBFF-41CA92855826"></a> <a name=
"section-7.4.10" id="section-7.4.10"></a>
<h3><span class="Bold Italics">Skin and Appendages</span></h3>
<p class="First"><span class="Italics">Frequent:</span> Pruritus;
<span class="Italics">infrequent:</span> Acne, alopecia, contact
dermatitis, dry skin, ecchymosis, eczema, herpes simplex,
photosensitivity, urticaria; <span class="Italics">rare:</span>
Angioedema, erythema nodosum, erythema multiforme, exfoliative
dermatitis, fungal dermatitis, furunculosis; herpes zoster,
hirsutism, maculopapular rash, seborrhea, skin discoloration, skin
hypertrophy, skin ulcer, sweating decreased, vesiculobullous
rash.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_02C1C7B9-8C09-67B6-F2CE-33982AC51011" id=
"_02C1C7B9-8C09-67B6-F2CE-33982AC51011"></a> <a name=
"section-7.4.11" id="section-7.4.11"></a>
<h3><span class="Bold Italics">Special Senses</span></h3>
<p class="First"><span class="Italics">Frequent</span>: Tinnitus;
<span class="Italics">infrequent:</span> Abnormality of
accommodation, conjunctivitis, ear pain, eye pain,
keratoconjunctivitis, mydriasis, otitis media; <span class=
"Italics">rare:</span> Amblyopia, anisocoria, blepharitis,
cataract, conjunctival edema, corneal ulcer, deafness,
exophthalmos, eye hemorrhage, glaucoma, hyperacusis, night
blindness, otitis externa, parosmia, photophobia, ptosis, retinal
hemorrhage, taste loss, visual field defect.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_3A53804C-66E5-1EA5-06E9-6613B00AEE74" id=
"_3A53804C-66E5-1EA5-06E9-6613B00AEE74"></a> <a name=
"section-7.4.12" id="section-7.4.12"></a>
<h3><span class="Bold Italics">Urogenital System</span></h3>
<p class="First"><span class="Italics">Infrequent:</span>
Amenorrhea, breast pain, cystitis, dysuria, hematuria, menorrhagia,
nocturia, polyuria, pyuria, urinary incontinence, urinary
retention, urinary urgency, vaginitis; <span class=
"Italics">rare:</span> Abortion, breast atrophy, breast
enlargement, endometrial disorder, epididymitis, female lactation,
fibrocystic breast, kidney calculus, kidney pain, leukorrhea,
mastitis, metrorrhagia, nephritis, oliguria, salpingitis,
urethritis, urinary casts, uterine spasm, urolith, vaginal
hemorrhage, vaginal moniliasis.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_2240740F-F4CF-D15F-14B6-E503FB5E3128" id=
"_2240740F-F4CF-D15F-14B6-E503FB5E3128"></a> <a name="section-7.5"
id="section-7.5"></a>
<h2>Postmarketing Reports</h2>
<p class="First">Voluntary reports of adverse events in patients
taking paroxetine that have been received since market introduction
and not listed above that may have no causal relationship with the
drug include acute pancreatitis, elevated liver function tests (the
most severe cases were deaths due to liver necrosis, and grossly
elevated transaminases associated with severe liver dysfunction),
Guillain-Barré syndrome, Stevens-Johnson syndrome, toxic epidermal
necrolysis, priapism, syndrome of inappropriate ADH secretion,
symptoms suggestive of prolactinemia and galactorrhea;
extrapyramidal symptoms which have included akathisia,
bradykinesia, cogwheel rigidity, dystonia, hypertonia, oculogyric
crisis which has been associated with concomitant use of pimozide;
tremor and trismus; status epilepticus, acute renal failure,
pulmonary hypertension, allergic alveolitis, anaphylaxis,
eclampsia, laryngismus, optic neuritis, porphyria, restless legs
syndrome (RLS), ventricular fibrillation, ventricular tachycardia
(including torsade de pointes), thrombocytopenia, hemolytic anemia,
events related to impaired hematopoiesis (including aplastic
anemia, pancytopenia, bone marrow aplasia, and agranulocytosis),
vasculitic syndromes (such as Henoch-Schönlein purpura), and
premature births in pregnant women. There has been a case report of
an elevated phenytoin level after 4 weeks of paroxetine and
phenytoin coadministration. There has been a case report of severe
hypotension when paroxetine was added to chronic metoprolol
treatment.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DRUG ABUSE AND DEPENDENCE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42227-9"><a name="_846552E8-CA12-95AA-67F6-8EF0A25FC12F" id=
"_846552E8-CA12-95AA-67F6-8EF0A25FC12F"></a> <a name="section-8"
id="section-8"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="34085-1"><a name=
"_BCECB2EA-1C14-3A50-E370-F73E0E78667B" id=
"_BCECB2EA-1C14-3A50-E370-F73E0E78667B"></a> <a name="section-8.1"
id="section-8.1"></a>
<h2>Controlled Substance Class</h2>
<p class="First">Paroxetine is not a controlled substance.</p>
</div>
<div class="Section" data-sectioncode="34087-7"><a name=
"_EE43A07D-D432-9956-F8E8-BB86342DC540" id=
"_EE43A07D-D432-9956-F8E8-BB86342DC540"></a> <a name="section-8.2"
id="section-8.2"></a>
<h2>Physical and Psychologic Dependence</h2>
<p class="First">Paroxetine has not been systematically studied in
animals or humans for its potential for abuse, tolerance or
physical dependence. While the clinical trials did not reveal any
tendency for any drug-seeking behavior, these observations were not
systematic and it is not possible to predict on the basis of this
limited experience the extent to which a CNS-active drug will be
misused, diverted, and/or abused once marketed. Consequently,
patients should be evaluated carefully for history of drug abuse,
and such patients should be observed closely for signs of misuse or
abuse of paroxetine (e.g., development of tolerance,
incrementations of dose, drug-seeking behavior).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="_91D936B2-EFAC-9E00-6DF9-3AEEDCF53535" id=
"_91D936B2-EFAC-9E00-6DF9-3AEEDCF53535"></a> <a name="section-9"
id="section-9"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D017C349-5474-8ED9-CE2D-3FC8F8144BEB" id=
"_D017C349-5474-8ED9-CE2D-3FC8F8144BEB"></a> <a name="section-9.1"
id="section-9.1"></a>
<h2>Human Experience</h2>
<p class="First">Since the introduction of paroxetine in the United
States, 342 spontaneous cases of deliberate or accidental
overdosage during paroxetine treatment have been reported worldwide
(circa 1999). These include overdoses with paroxetine alone and in
combination with other substances. Of these, 48 cases were fatal
and of the fatalities, 17 appeared to involve paroxetine alone.
Eight fatal cases that documented the amount of paroxetine ingested
were generally confounded by the ingestion of other drugs or
alcohol or the presence of significant comorbid conditions. Of 145
non-fatal cases with known outcome, most recovered without
sequelae. The largest known ingestion involved 2,000 mg of
paroxetine (33 times the maximum recommended daily dose) in a
patient who recovered.</p>
<p>Commonly reported adverse events associated with paroxetine
overdosage include somnolence, coma, nausea, tremor, tachycardia,
confusion, vomiting, and dizziness. Other notable signs and
symptoms observed with overdoses involving paroxetine (alone or
with other substances) include mydriasis, convulsions (including
status epilepticus), ventricular dysrhythmias (including torsade de
pointes), hypertension, aggressive reactions, syncope, hypotension,
stupor, bradycardia, dystonia, rhabdomyolysis, symptoms of hepatic
dysfunction (including hepatic failure, hepatic necrosis, jaundice,
hepatitis, and hepatic steatosis), serotonin syndrome, manic
reactions, myoclonus, acute renal failure, and urinary
retention.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_146F7D1F-F837-82C0-A527-6360E1A2C035" id=
"_146F7D1F-F837-82C0-A527-6360E1A2C035"></a> <a name="section-9.2"
id="section-9.2"></a>
<h2>Overdosage Management</h2>
<p class="First">No specific antidotes for paroxetine are known.
Treatment should consist of those general measures employed in the
management of overdosage with any drugs effective in the treatment
of major depressive disorder.</p>
<p>Ensure an adequate airway, oxygenation, and ventilation. Monitor
cardiac rhythm and vital signs. General supportive and symptomatic
measures are also recommended. Induction of emesis is not
recommended. Due to the large volume of distribution of this drug,
forced diuresis, dialysis, hemoperfusion, or exchange transfusion
are unlikely to be of benefit.</p>
<p>A specific caution involves patients who are taking or have
recently taken paroxetine who might ingest excessive quantities of
a tricyclic antidepressant. In such a case, accumulation of the
parent tricyclic and/or an active metabolite may increase the
possibility of clinically significant sequelae and extend the time
needed for close medical observation (see <span class=
"Bold"><a href=
"#_EB6A5107-B86F-F470-348B-CF35F9F9A0CA">PRECAUTIONS,</a></span>
<span class="Bold Italics"><a href=
"#_EB6A5107-B86F-F470-348B-CF35F9F9A0CA">Drugs Metabolized by
Cytochrome CYP2D6</a></span>).</p>
<p>In managing overdosage, consider the possibility of multiple
drug involvement. The physician should consider contacting a poison
control center for additional information on the treatment of any
overdose. Telephone numbers for certified poison control centers
are listed in the <span class="Italics">Physicians' Desk
Reference</span> (PDR).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="_CB52CA1B-9E5C-4EE9-409E-70225180C0EB" id=
"_CB52CA1B-9E5C-4EE9-409E-70225180C0EB"></a> <a name="section-10"
id="section-10"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_4A47D439-B02A-B20F-8B6B-B1FDC8366619" id=
"_4A47D439-B02A-B20F-8B6B-B1FDC8366619"></a> <a name="section-10.1"
id="section-10.1"></a>
<h2>Major Depressive Disorder</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_91CCCA9A-1A46-A78F-F4A5-808AB6606847" id=
"_91CCCA9A-1A46-A78F-F4A5-808AB6606847"></a> <a name=
"section-10.1.1" id="section-10.1.1"></a>
<h3><span class="Bold Italics">Usual Initial Dosage</span></h3>
<p class="First">Paroxetine should be administered as a single
daily dose with or without food, usually in the morning. The
recommended initial dose is 20 mg/day. Patients were dosed in a
range of 20 to 50 mg/day in the clinical trials demonstrating the
effectiveness of paroxetine in the treatment of major depressive
disorder. As with all drugs effective in the treatment of major
depressive disorder, the full effect may be delayed. Some patients
not responding to a 20-mg dose may benefit from dose increases, in
10-mg/day increments, up to a maximum of 50 mg/day. Dose changes
should occur at intervals of at least 1 week.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_01E9E851-2262-E9C0-A1A1-761FBDA95395" id=
"_01E9E851-2262-E9C0-A1A1-761FBDA95395"></a> <a name=
"section-10.1.2" id="section-10.1.2"></a>
<h3><span class="Bold Italics">Maintenance Therapy</span></h3>
<p class="First">There is no body of evidence available to answer
the question of how long the patient treated with paroxetine should
remain on it. It is generally agreed that acute episodes of major
depressive disorder require several months or longer of sustained
pharmacologic therapy. Whether the dose needed to induce remission
is identical to the dose needed to maintain and/or sustain euthymia
is unknown.</p>
<p>Systematic evaluation of the efficacy of paroxetine has shown
that efficacy is maintained for periods of up to 1 year with doses
that averaged about 30 mg.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_23AF0DBF-8037-ACEC-DF81-EFECA0AF3E54" id=
"_23AF0DBF-8037-ACEC-DF81-EFECA0AF3E54"></a> <a name="section-10.2"
id="section-10.2"></a>
<h2>Obsessive Compulsive Disorder</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_B825FFB8-627A-ADA7-79A1-1C8526DBEA87" id=
"_B825FFB8-627A-ADA7-79A1-1C8526DBEA87"></a> <a name=
"section-10.2.1" id="section-10.2.1"></a>
<h3><span class="Bold Italics">Usual Initial Dosage</span></h3>
<p class="First">Paroxetine should be administered as a single
daily dose with or without food, usually in the morning. The
recommended dose of paroxetine in the treatment of OCD is 40 mg
daily. Patients should be started on 20 mg/day and the dose can be
increased in 10-mg/day increments. Dose changes should occur at
intervals of at least 1 week. Patients were dosed in a range of 20
to 60 mg/day in the clinical trials demonstrating the effectiveness
of paroxetine in the treatment of OCD. The maximum dosage should
not exceed 60 mg/day.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_31AAC9DF-583A-A7D1-D5C8-16B471C817EE" id=
"_31AAC9DF-583A-A7D1-D5C8-16B471C817EE"></a> <a name=
"section-10.2.2" id="section-10.2.2"></a>
<h3><span class="Bold Italics">Maintenance Therapy</span></h3>
<p class="First">Long-term maintenance of efficacy was demonstrated
in a 6-month relapse prevention trial. In this trial, patients with
OCD assigned to paroxetine demonstrated a lower relapse rate
compared to patients on placebo (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>). OCD is a chronic condition, and it is
reasonable to consider continuation for a responding patient.
Dosage adjustments should be made to maintain the patient on the
lowest effective dosage, and patients should be periodically
reassessed to determine the need for continued treatment.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_57FDBE88-F817-A25E-6784-3EAA5276440C" id=
"_57FDBE88-F817-A25E-6784-3EAA5276440C"></a> <a name="section-10.3"
id="section-10.3"></a>
<h2>Panic Disorder</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_110AAEDD-00A7-E558-748B-C11718C7A82F" id=
"_110AAEDD-00A7-E558-748B-C11718C7A82F"></a> <a name=
"section-10.3.1" id="section-10.3.1"></a>
<h3><span class="Bold Italics">Usual Initial Dosage</span></h3>
<p class="First">Paroxetine should be administered as a single
daily dose with or without food, usually in the morning. The target
dose of paroxetine in the treatment of panic disorder is 40 mg/day.
Patients should be started on 10 mg/day. Dose changes should occur
in 10-mg/day increments and at intervals of at least 1 week.
Patients were dosed in a range of 10 to 60 mg/day in the clinical
trials demonstrating the effectiveness of paroxetine. The maximum
dosage should not exceed 60 mg/day.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_A19D09AB-148C-035A-A72A-FA0315F7F4CB" id=
"_A19D09AB-148C-035A-A72A-FA0315F7F4CB"></a> <a name=
"section-10.3.2" id="section-10.3.2"></a>
<h3><span class="Bold Italics">Maintenance Therapy</span></h3>
<p class="First">Long-term maintenance of efficacy was demonstrated
in a 3-month relapse prevention trial. In this trial, patients with
panic disorder assigned to paroxetine demonstrated a lower relapse
rate compared to patients on placebo (see <span class=
"Bold"><a href="#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL
PHARMACOLOGY, Clinical Trials</a></span>). Panic disorder is a
chronic condition, and it is reasonable to consider continuation
for a responding patient. Dosage adjustments should be made to
maintain the patient on the lowest effective dosage, and patients
should be periodically reassessed to determine the need for
continued treatment.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_F2EE24E3-9C2B-6D65-781E-E97881D6A53B" id=
"_F2EE24E3-9C2B-6D65-781E-E97881D6A53B"></a> <a name="section-10.4"
id="section-10.4"></a>
<h2>Social Anxiety Disorder</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_C6111F10-014E-A062-B24A-E4ED41B53912" id=
"_C6111F10-014E-A062-B24A-E4ED41B53912"></a> <a name=
"section-10.4.1" id="section-10.4.1"></a>
<h3><span class="Bold Italics">Usual Initial Dosage</span></h3>
<p class="First">Paroxetine should be administered as a single
daily dose with or without food, usually in the morning. The
recommended and initial dosage is 20 mg/day. In clinical trials the
effectiveness of paroxetine was demonstrated in patients dosed in a
range of 20 to 60 mg/day. While the safety of paroxetine has been
evaluated in patients with social anxiety disorder at doses up to
60 mg/day, available information does not suggest any additional
benefit for doses above 20 mg/day (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9109A725-12F2-DAE8-FE0E-771397647CA6" id=
"_9109A725-12F2-DAE8-FE0E-771397647CA6"></a> <a name=
"section-10.4.2" id="section-10.4.2"></a>
<h3><span class="Bold Italics">Maintenance Therapy</span></h3>
<p class="First">There is no body of evidence available to answer
the question of how long the patient treated with paroxetine should
remain on it. Although the efficacy of paroxetine beyond 12 weeks
of dosing has not been demonstrated in controlled clinical trials,
social anxiety disorder is recognized as a chronic condition, and
it is reasonable to consider continuation of treatment for a
responding patient. Dosage adjustments should be made to maintain
the patient on the lowest effective dosage, and patients should be
periodically reassessed to determine the need for continued
treatment.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_A9168549-B7AB-333E-BD77-BB013E2FB757" id=
"_A9168549-B7AB-333E-BD77-BB013E2FB757"></a> <a name="section-10.5"
id="section-10.5"></a>
<h2>Generalized Anxiety Disorder</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_48035A93-D186-149F-12B9-4A0BE8E011CA" id=
"_48035A93-D186-149F-12B9-4A0BE8E011CA"></a> <a name=
"section-10.5.1" id="section-10.5.1"></a>
<h3><span class="Bold Italics">Usual Initial Dosage</span></h3>
<p class="First">Paroxetine should be administered as a single
daily dose with or without food, usually in the morning. In
clinical trials the effectiveness of paroxetine was demonstrated in
patients dosed in a range of 20 to 50 mg/day. The recommended
starting dosage and the established effective dosage is 20 mg/day.
There is not sufficient evidence to suggest a greater benefit to
doses higher than 20 mg/day. Dose changes should occur in 10 mg/day
increments and at intervals of at least 1 week.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_E09D00DD-6FFF-DE3F-978F-29B8782EFF35" id=
"_E09D00DD-6FFF-DE3F-978F-29B8782EFF35"></a> <a name=
"section-10.5.2" id="section-10.5.2"></a>
<h3><span class="Bold Italics">Maintenance Therapy</span></h3>
<p class="First">Systematic evaluation of continuing paroxetine for
periods of up to 24 weeks in patients with Generalized Anxiety
Disorder who had responded while taking paroxetine during an 8-week
acute treatment phase has demonstrated a benefit of such
maintenance (see <span class="Bold"><a href=
"#_B643AA0D-BCAD-CB26-AC86-6BE333846CA0">CLINICAL PHARMACOLOGY,
Clinical Trials</a></span>). Nevertheless, patients should be
periodically reassessed to determine the need for maintenance
treatment.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_D6898B93-D36B-08DE-932F-9AF422F78FAD" id=
"_D6898B93-D36B-08DE-932F-9AF422F78FAD"></a> <a name="section-10.6"
id="section-10.6"></a>
<h2>Special Populations</h2>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_9E6BE420-A0F9-5BE3-3805-32F3D6761830" id=
"_9E6BE420-A0F9-5BE3-3805-32F3D6761830"></a> <a name=
"section-10.6.1" id="section-10.6.1"></a>
<h3><span class="Bold Italics">Treatment of Pregnant Women During
the Third Trimester</span></h3>
<p class="First">Neonates exposed to paroxetine and other SSRIs or
SNRIs, late in the third trimester have developed complications
requiring prolonged hospitalization, respiratory support, and tube
feeding (see <span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS, Usage in
Pregnancy</a></span>). When treating pregnant women with paroxetine
during the third trimester, the physician should carefully consider
the potential risks and benefits of treatment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_EF2851EB-6852-2F9E-B30E-36FB2775D70E" id=
"_EF2851EB-6852-2F9E-B30E-36FB2775D70E"></a> <a name=
"section-10.6.2" id="section-10.6.2"></a>
<h3><span class="Bold Italics">Dosage for Elderly or Debilitated
Patients, and Patients With Severe Renal or Hepatic
Impairment</span></h3>
<p class="First">The recommended initial dose is 10 mg/day for
elderly patients, debilitated patients, and/or patients with severe
renal or hepatic impairment. Increases may be made if indicated.
Dosage should not exceed 40 mg/day.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_2E666982-A67F-ED7E-AD28-DFBCA8655F69" id=
"_2E666982-A67F-ED7E-AD28-DFBCA8655F69"></a> <a name="section-10.7"
id="section-10.7"></a>
<h2><span class="Bold">Switching</span> <span class="Bold">a
Patient</span> <span class="Bold">to or From a Monoamine Oxidase
Inhibitor</span> <span class="Bold">(MAOI) Intended to Treat
Psychiatric Disorders:</span></h2>
<p class="First">At least 14 days should elapse between
discontinuation of an MAOI intended to treat psychiatric disorders
and initiation of therapy with paroxetine Conversely, at least 14
days should be allowed after stopping paroxetine before starting an
MAOI intended to treat psychiatric disorders (see <span class=
"Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_d03f0473-09bb-dadf-f6be-99d5f001e81b" id=
"_d03f0473-09bb-dadf-f6be-99d5f001e81b"></a> <a name="section-10.8"
id="section-10.8"></a>
<h2><span class="Bold">Use of Paroxetine With Other MAOIs, Such as
Linezolid or Methylene Blue</span></h2>
<p class="First">Do not start paroxetine tablets in a patient who
is being treated with linezolid or intravenous methylene blue
because there is increased risk of serotonin syndrome. In a patient
who requires more urgent treatment of a psychiatric condition,
other interventions, including hospitalization, should be
considered (see <span class="Bold"><a href=
"#_49158A19-DB4A-CA1C-9F32-848D196EBDF7">CONTRAINDICATIONS</a></span>).</p>
<p>In some cases, a patient already receiving therapy with
paroxetine tablets may require urgent treatment with linezolid or
intravenous methylene blue. If acceptable alternatives to linezolid
or intravenous methylene blue treatment are not available and the
potential benefits of linezolid or intravenous methylene blue
treatment are judged to outweigh the risks of serotonin syndrome in
a particular patient, paroxetine tablets should be stopped
promptly, and linezolid or intravenous methylene blue can be
administered. The patient should be monitored for symptoms of
serotonin syndrome for 2 weeks or until 24 hours after the last
dose of linezolid or intravenous methylene blue, whichever comes
first. Therapy with paroxetine tablets may be resumed 24 hours
after the last dose of linezolid or intravenous methylene blue (see
<span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span>).</p>
<p>The risk of administering methylene blue by non-intravenous
routes (such as oral tablets or by local injection) or in
intravenous doses much lower than 1 mg/kg with paroxetine is
unclear. The clinician should, nevertheless, be aware of the
possibility of emergent symptoms of serotonin syndrome with such
use (see <span class="Bold"><a href=
"#_43D3F4B6-1241-968E-D33D-EEB9737A9D17">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"_305DC541-8AB2-7CBF-8D1C-0360CB638700" id=
"_305DC541-8AB2-7CBF-8D1C-0360CB638700"></a> <a name="section-10.9"
id="section-10.9"></a>
<h2>Discontinuation of Treatment With Paroxetine</h2>
<p class="First">Symptoms associated with discontinuation of
paroxetine have been reported (see <span class="Bold"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">PRECAUTIONS:</a></span>
<span class="Bold Italics"><a href=
"#_4FF5DBBC-18A8-25DE-4CFE-A55D63D25A84">Discontinuation of
Treatment With Paroxetine</a></span>). Patients should be monitored
for these symptoms when discontinuing treatment, regardless of the
indication for which paroxetine is being prescribed. A gradual
reduction in the dose rather than abrupt cessation is recommended
whenever possible. If intolerable symptoms occur following a
decrease in the dose or upon discontinuation of treatment, then
resuming the previously prescribed dose may be considered.
Subsequently, the physician may continue decreasing the dose but at
a more gradual rate.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HOW SUPPLIED</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="_74D7E066-AB1D-48D6-D7BF-BF1C347657D3" id=
"_74D7E066-AB1D-48D6-D7BF-BF1C347657D3"></a> <a name="section-11"
id="section-11"></a>
<p class="First">Paroxetine tablets, USP are supplied as white to
off-white, oval, film-coated tablets as follows:</p>
<p>10 mg scored tablets imprinted “APO” with a partial bisect on
one side and “097” on the other side. NDC 60505-0097-1 Bottles of
30; NDC 60505-0097-9 Bottles of 90; NDC 60505-0097-2 Bottles of
100; NDC 60505-0097-4 Bottles of 1000; NDC 60505-0097-7 Bottles of
18,000; NDC 60505-0097-5 Unit dose blisters, package of 100
(10x10).</p>
<p>20 mg scored tablets imprinted “APO” with a partial bisect score
on one side and “083” on the other side. NDC 60505-0083-1 Bottles
of 30; NDC 60505-0083-9 Bottles of 90; NDC 60505-0083-2 Bottles of
100; NDC 60505-0083-4 Bottles of 1000; NDC 60505-0083-0 Bottles of
12,500; NDC 60505-0083-5 Unit dose blisters, package of 100
(10x10).</p>
<p>30 mg unscored tablets imprinted “APO” on one side and “084” on
the other side. NDC 60505-0084-1 Bottles of 30; NDC 60505-0084-9
Bottles of 90; NDC 60505-0084-2 Bottles of 100; NDC 60505-0084-4
Bottles of 1000; NDC 60505-0084-5 Unit dose blisters, package of
100 (10x10).</p>
<p>40 mg unscored tablets imprinted “APO” on one side and “101” on
the other side. NDC 60505-0101-1 Bottles of 30; NDC 60505-0101-9
Bottles of 90; NDC 60505-0101-2 Bottles of 100; NDC 60505-0101-4
Bottles of 1000; NDC 60505-0101-5 Unit dose blisters, package of
100 (10x10).</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15°
to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container [see USP].</p>
<p><span class="Bold"><br>
APOTEX INC.</span><br>
<span class="Bold">PAROXETINE TABLETS, USP</span><br>
<span class="Bold">10 mg, 20 mg, 30 mg and 40 mg</span></p>
<p><span class="Bold"><br>
Manufactured by Manufactured for</span></p>
<p>Apotex Inc. Apotex Corp.</p>
<p>Toronto, Ontario Weston,</p>
<p>Canada Florida</p>
<p>M9L 1T9 33326</p>
<p><br>
Revised: August 2014</p>
<p>Rev. 11</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">MEDICATION GUIDE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42231-1"><a name="_a22f8456-aebb-45e0-7d12-d3edce90e2b7" id=
"_a22f8456-aebb-45e0-7d12-d3edce90e2b7"></a> <a name="section-12"
id="section-12"></a>
<p class="First"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"_0909f475-447a-8424-3b15-81c1aeae49cc" id=
"_0909f475-447a-8424-3b15-81c1aeae49cc"></a> <a name="section-12.1"
id="section-12.1"></a>
<h2>Paroxetine Tablets, USP<br>
<span class="None">(pa rox’ e teen)</span></h2>
<p class="First">Read the Medication Guide that comes with
paroxetine before you start taking it and each time you get a
refill. There may be new information. This Medication Guide does
not take the place of talking to your healthcare provider about
your medical condition or treatment. Talk with your healthcare
provider if there is something you do not understand or want to
learn more about.</p>
<p><span class="Bold">What is the most important information I
should know about paroxetine?</span></p>
<p>Paroxetine and other antidepressant medicines may cause serious
side effects, including:</p>
<p>1. <span class="Bold">Suicidal thoughts or actions:</span></p>
<ul>
<li><span class="Bold">Paroxetine and other antidepressant
medicines may increase suicidal thoughts or actions</span> in some
children, teenagers, or young adults within the <span class=
"Bold">first few months of treatment or when the dose is
changed</span>.</li>
<li>Depression or other serious mental illnesses are the most
important causes of suicidal thoughts or actions.</li>
<li>Watch for these changes and call your healthcare provider right
away if you notice:
<ul>
<li>New or sudden changes in mood, behavior, actions, thoughts, or
feelings, especially if severe.</li>
<li>Pay particular attention to such changes when paroxetine is
started or when the dose is changed.</li>
</ul>
</li>
</ul>
<p>Keep all follow-up visits with your healthcare provider and call
between visits if you are worried about symptoms.</p>
<p><span class="Bold">Call your healthcare provider right away if
you have any of the following symptoms, or call 911 if an
emergency, especially if they are new, worse, or worry
you:</span></p>
<ul>
<li>attempts to commit suicide</li>
<li>acting on dangerous impulses</li>
<li>acting aggressive or violent</li>
<li>thoughts about suicide or dying</li>
<li>new or worse depression</li>
<li>new or worse anxiety or panic attacks</li>
<li>feeling agitated, restless, angry, or irritable</li>
<li>trouble sleeping</li>
<li>an increase in activity or talking more than what is normal for
you</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if
you have any of the following symptoms, or call 911 if an
emergency. Paroxetine may be associated with these serious side
effects:</span></p>
<p>2. <span class="Bold">Serotonin Syndrome or Neuroleptic
Malignant Syndrome-like reactions. This condition can be
life-threatening and may</span> <span class=
"Bold">include:</span></p>
<ul>
<li>agitation, hallucinations, coma, or other changes in mental
status</li>
<li>coordination problems or muscle twitching (overactive
reflexes)</li>
<li>racing heartbeat, high or low blood pressure</li>
<li>sweating or fever</li>
<li>nausea, vomiting, or diarrhea</li>
<li>muscle rigidity</li>
</ul>
<p>3. <span class="Bold">Visual problems</span></p>
<ul>
<li>eye pain</li>
<li>changes in vision</li>
<li>swelling or redness in or around the eye</li>
</ul>
<p>Only some people are at risk for these problems. You may want to
undergo an eye examination to see if you are at risk and receive
preventative treatment if you are.</p>
<p>4. <span class="Bold">Severe allergic reactions:</span></p>
<ul>
<li>trouble breathing</li>
<li>swelling of the face, tongue, eyes, or mouth</li>
<li>rash, itchy welts (hives), or blisters, alone or with fever or
joint pain</li>
</ul>
<p>5. <span class="Bold">Abnormal bleeding:</span> Paroxetine and
other antidepressant medicines may increase your risk of bleeding
or bruising, especially if you take the blood thinner warfarin
(Coumadin<span class="Sup">®</span>, Jantoven<span class=
"Sup">®</span>), a non-steroidal anti-inflammatory drug (NSAIDs,
like ibuprofen or naproxen), or aspirin.</p>
<p>6. <span class="Bold">Seizures or convulsions</span></p>
<p>7. <span class="Bold">Manic episodes</span>:</p>
<ul>
<li>greatly increased energy</li>
<li>severe trouble sleeping</li>
<li>racing thoughts</li>
<li>reckless behavior</li>
<li>unusually grand ideas</li>
<li>excessive happiness or irritability</li>
<li>talking more or faster than usual</li>
</ul>
<p>8. <span class="Bold">Changes in appetite or weight.</span>
Children and adolescents should have height and weight monitored
during treatment.</p>
<p>9. <span class="Bold">Low salt (sodium) levels in the
blood.</span> Elderly people may be at greater risk for this.
Symptoms may include:</p>
<ul>
<li>headache</li>
<li>weakness or feeling unsteady</li>
<li>confusion, problems concentrating or thinking, or memory
problems</li>
</ul>
<p><span class="Bold">Do not stop paroxetine without first talking
to your healthcare provider.</span> Stopping paroxetine too quickly
may cause serious symptoms including:</p>
<ul>
<li>anxiety, irritability, high or low mood, feeling restless, or
changes in sleep habits</li>
<li>headache, sweating, nausea, dizziness</li>
<li>electric shock-like sensations, shaking, confusion</li>
</ul>
<p><span class="Bold">What is paroxetine?</span></p>
<p>Paroxetine is a prescription medicine used to treat
depression<span class="Underline">.</span> It is important to talk
with your healthcare provider about the risks of treating
depression and also the risks of not treating it. You should
discuss all treatment choices with your healthcare provider.
Paroxetine is <span class="Underline">also</span> used to
treat:</p>
<ul>
<li>Major Depressive Disorder (MDD)</li>
<li>Obsessive Compulsive Disorder (OCD)</li>
<li>Panic Disorder</li>
<li>Social Anxiety Disorder</li>
<li>Generalized Anxiety Disorder (GAD)</li>
</ul>
<p>Talk to your healthcare provider if you do not think that your
condition is getting better with treatment using paroxetine.</p>
<p><span class="Bold">Who should not take paroxetine?</span></p>
<p>Do not take paroxetine if you:</p>
<ul>
<li>are allergic to paroxetine or any of the ingredients in
paroxetine tablets. See the end of this Medication Guide for a
complete list of ingredients in paroxetine tablets.</li>
<li>take a monoamine oxidase inhibitor (MAOI). Ask your healthcare
provider or pharmacist if you are not sure if you take an MAOI,
including the antibiotic linezolid.
<ul>
<li>Do not take an MAOI within 2 weeks of stopping paroxetine
unless directed to do so by your physician.</li>
<li>Do not start paroxetine if you stopped taking an MAOI in the
last 2 weeks unless directed to do so by your physician.</li>
<li>People who take paroxetine close in time to an MAOI may have
serious or even life-threatening side effects. Get medical help
right away if you have any of these symptoms:
<ul>
<li>high fever</li>
<li>uncontrolled muscle spasms</li>
<li>stiff muscles</li>
<li>rapid changes in heart rate or blood pressure</li>
<li>confusion</li>
<li>loss of consciousness (pass out)</li>
</ul>
</li>
</ul>
</li>
</ul>
<ul>
<li><span class="Bold">take MELLARIL</span><span class=
"Sup">®</span> <span class="Bold">(thioridazine). Do not take
MELLARIL</span><span class="Sup">®</span> <span class=
"Bold">together with paroxetine because this can cause serious
heart rhythm problems or sudden death.</span></li>
<li><span class="Bold">take the antipsychotic medicine pimozide
(ORAP</span><span class="Sup">®</span><span class="Bold">) because
this can cause serious heart problems.</span></li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider
before taking paroxetine? Ask if you are not sure.</span></p>
<p>Before starting paroxetine, tell your healthcare provider if
you:</p>
<ul>
<li><span class="Bold">are pregnant, may be pregnant, or plan to
become pregnant.</span> There is a possibility that paroxetine may
harm your unborn baby, including an increased risk of birth
defects, particularly heart defects. Other risks may include a
serious condition in which there is not enough oxygen in the baby’s
blood. Your baby may also have certain other symptoms shortly after
birth. Premature births have also been reported in some women who
used paroxetine during pregnancy.</li>
<li><span class="Bold">are breastfeeding.</span> Paroxetine passes
into your milk. Talk to your healthcare provider about the best way
to feed your baby while taking paroxetine.</li>
<li>are taking certain drugs such as:
<ul>
<li>triptans used to treat migraine headache</li>
<li>other antidepressants (SSRIs, SNRIs, tricyclics, or lithium) or
antipsychotics</li>
<li>drugs that affect serotonin, such as lithium, tramadol,
tryptophan, St. John’s wort</li>
<li>certain drugs used to treat irregular heart beats</li>
<li>certain drugs used to treat schizophrenia</li>
<li>certain drugs used to treat HIV infection</li>
<li>certain drugs that affect the blood, such as warfarin, aspirin,
and ibuprofen</li>
<li>certain drugs used to treat epilepsy</li>
<li>atomoxetine</li>
<li>cimetidine</li>
<li>fentanyl</li>
<li>metoprolol</li>
<li>pimozide</li>
<li>procyclidine</li>
<li>tamoxifen</li>
<li>have liver problems</li>
<li>have kidney problems</li>
<li>have heart problems</li>
<li>have or had seizures or convulsions</li>
<li>have bipolar disorder or mania</li>
<li>have low sodium levels in your blood</li>
<li>have a history of a stroke</li>
<li>have high blood pressure</li>
<li>have or had bleeding problems</li>
<li>have glaucoma (high pressure in the eye)</li>
</ul>
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the
medicines you take</span>, including prescription and
non-prescription medicines, vitamins, and herbal supplements.
Paroxetine and some medicines may interact with each other, may not
work as well, or may cause serious side effects.</p>
<p>Your healthcare provider or pharmacist can tell you if it is
safe to take paroxetine with your other medicines. Do not start or
stop any medicine while taking paroxetine without talking to your
healthcare provider first.</p>
<div class="scrollingtable">
<table frame="box">
<tbody class="Headless">
<tr class="First Last">
<td colspan="2">If you take paroxetine, you should not take any
other medicines that contain paroxetine hydrochloride, including
PAXIL CR and PEXEVA<span class="Sup">®</span> (paroxetine
mesylate).</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">How should I take paroxetine?</span></p>
<ul>
<li>Take paroxetine exactly as prescribed. Your healthcare provider
may need to change the dose of paroxetine until it is the right
dose for you.</li>
<li>Paroxetine may be taken with or without food.</li>
<li>If you are taking paroxetine oral suspension, shake the
suspension well before use.</li>
<li>If you miss a dose of paroxetine, take the missed dose as soon
as you remember. If it is almost time for the next dose, skip the
missed dose and take your next dose at the regular time. Do not
take two doses of paroxetine at the same time.</li>
<li>If you take too much paroxetine, call your healthcare provider
or poison control center right away, or get emergency
treatment.</li>
<li>Do not stop taking paroxetine suddenly without talking to your
doctor (unless you have symptoms of a severe allergic reaction). If
you need to stop taking paroxetine, your healthcare provider can
tell you how to safely stop taking it.</li>
</ul>
<p><span class="Bold">What should I avoid while taking
paroxetine?</span></p>
<p>Paroxetine can cause sleepiness or may affect your ability to
make decisions, think clearly, or react quickly. You should not
drive, operate heavy machinery, or do other dangerous activities
until you know how paroxetine affects you. Do not drink alcohol
while using paroxetine.</p>
<p><span class="Bold">What are possible side effects of</span>
<span class="Bold">paroxetine?</span></p>
<p>Paroxetine may cause serious side effects, including all of
those described in the section entitled “What is the most important
information I should know about paroxetine?”</p>
<p>Common possible side effects in people who take paroxetine
include:</p>
<ul>
<li>nausea</li>
<li>sleepiness</li>
<li>weakness</li>
<li>dizziness</li>
<li>feeling anxious or trouble sleeping</li>
<li>sexual problems</li>
<li>sweating</li>
<li>shaking</li>
<li>not feeling hungry</li>
<li>dry mouth</li>
<li>constipation</li>
<li>infection</li>
<li>yawning</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that
bothers you or that does not go away. These are not all the
possible side effects of paroxetine. For more information, ask your
healthcare provider or pharmacist.</p>
<p><span class="Bold">CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT
SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT
1-800-FDA­-1088 or 1-800-332-1088.</span></p>
<p><span class="Bold">How should I store paroxetine?</span></p>
<ul>
<li>Store at 20º to 25ºC (68º to 77ºF).</li>
<li>Keep paroxetine away from light.</li>
<li>Keep bottle of paroxetine closed tightly.</li>
</ul>
<p><span class="Bold">Keep paroxetine and all medicines out of the
reach of children.</span></p>
<p><span class="Bold">General information about
paroxetine</span></p>
<p>Medicines are sometimes prescribed for purposes other than those
listed in a Medication Guide. Do not use paroxetine for a condition
for which it was not prescribed. Do not give paroxetine to other
people, even if they have the same condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information
about paroxetine. If you would like more information, talk with
your healthcare provider. You may ask your healthcare provider or
pharmacist for information about paroxetine that is written for
healthcare professionals.</p>
<p>For more information about paroxetine call Apotex Drug
Information at 1-­800-706-5575.</p>
<p><span class="Bold">What are the ingredients in paroxetine
tablets?</span></p>
<p><span class="Bold">Active ingredient:</span> paroxetine
hydrochloride</p>
<p><span class="Bold">Inactive ingredients:</span> anhydrous
lactose, hydroxypropyl cellulose, hypromellose, magnesium stearate,
polyethylene glycol, sodium starch glycolate and titanium
dioxide.</p>
<p>PAXIL and PAXIL CR are registered trademarks of GlaxoSmithKline.
The other brands listed are trademarks of their respective owners.
This Medication Guide has been approved by the U.S. Food and Drug
Administration.</p>
<p><span class="Bold"><br>
Manufactured by Manufactured for</span></p>
<p>Apotex Inc. Apotex Corp.</p>
<p>Toronto, Ontario Weston, FL</p>
<p>Canada M9L 1T9 33326</p>
<p><br>
Revised: August 2014</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 10 mg BOTTLE LABEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="_6b71486c-9bdf-1862-6ef3-e54e14b3cb1d" id=
"_6b71486c-9bdf-1862-6ef3-e54e14b3cb1d"></a> <a name="section-13"
id="section-13"></a>
<p class="First"><span class="Bold">APOTEX CORP.</span> NDC
60505-0097-1</p>
<p><span class="Bold">PAROXETINE TABLETS, USP</span></p>
<p><span class="Bold">10 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p>30 Tablets</p>
<p><img src=
"image.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;name=10mg-30s-btl.jpg"
alt="10mg-30s-btl"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 20 mg BOTTLE LABEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="_ca7a314a-2449-c1a4-f40b-d8ee588966f0" id=
"_ca7a314a-2449-c1a4-f40b-d8ee588966f0"></a> <a name="section-14"
id="section-14"></a>
<p class="First"><span class="Bold">APOTEX CORP.</span> NDC
60505-0083-1</p>
<p><span class="Bold">PAROXETINE TABLETS, USP</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p>30 Tablets</p>
<p><img src=
"image.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;name=20mg-30s-btl.jpg"
alt="20mg-30s-btl"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 30 mg BOTTLE LABEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="_ed080c1d-3e78-dc06-690c-5088c20460bd" id=
"_ed080c1d-3e78-dc06-690c-5088c20460bd"></a> <a name="section-15"
id="section-15"></a>
<p class="First"><span class="Bold">APOTEX CORP.</span> NDC
60505-0084-1</p>
<p><span class="Bold">PAROXETINE TABLETS, USP</span></p>
<p><span class="Bold">30 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p>30 Tablets</p>
<p><img src=
"image.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;name=30mg-30s-btl.jpg"
alt="30mg-30s-btl"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 40 mg BOTTLE LABEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="_46fdd3f1-66db-bc67-75b0-11d7ef4eaec7" id=
"_46fdd3f1-66db-bc67-75b0-11d7ef4eaec7"></a> <a name="section-16"
id="section-16"></a>
<p class="First"><span class="Bold">APOTEX CORP.</span> NDC
60505-0101-1</p>
<p><span class="Bold">PAROXETINE TABLETS, USP</span></p>
<p><span class="Bold">40 mg</span></p>
<p><span class="Bold">Rx</span></p>
<p>30 Tablets</p>
<p><img src=
"image.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81&amp;name=40mg-30s-btl.jpg"
alt="40mg-30s-btl"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PAROXETINE</strong><br>
<span class="contentTableReg">paroxetine hydrochloride tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0097</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PAROXETINE HYDROCHLORIDE
ANHYDROUS</strong> (UNII: 3I3T11UD2S) (PAROXETINE -
UNII:41VRH5220H)</td>
<td class="formItem">PAROXETINE</td>
<td class="formItem">10 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE
H)</strong> (UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A
POTATO</strong> (UNII: 5856J3G2A2)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;097</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:60505-0097-1</td>
<td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:60505-0097-9</td>
<td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:60505-0097-2</td>
<td class="formItem">100 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:60505-0097-4</td>
<td class="formItem">1000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem">NDC:60505-0097-7</td>
<td class="formItem">18000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">6</th>
<td class="formItem">NDC:60505-0097-5</td>
<td class="formItem">10 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">6</th>
<td class="formItem"></td>
<td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075356</td>
<td class="formItem">09/08/2003</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PAROXETINE</strong><br>
<span class="contentTableReg">paroxetine hydrochloride tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0083</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PAROXETINE HYDROCHLORIDE
ANHYDROUS</strong> (UNII: 3I3T11UD2S) (PAROXETINE -
UNII:41VRH5220H)</td>
<td class="formItem">PAROXETINE</td>
<td class="formItem">20 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE
H)</strong> (UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A
POTATO</strong> (UNII: 5856J3G2A2)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;083</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:60505-0083-1</td>
<td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:60505-0083-9</td>
<td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:60505-0083-2</td>
<td class="formItem">100 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:60505-0083-4</td>
<td class="formItem">1000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem">NDC:60505-0083-0</td>
<td class="formItem">12500 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">6</th>
<td class="formItem">NDC:60505-0083-5</td>
<td class="formItem">10 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">6</th>
<td class="formItem"></td>
<td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075356</td>
<td class="formItem">09/08/2003</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PAROXETINE</strong><br>
<span class="contentTableReg">paroxetine hydrochloride tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0084</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PAROXETINE HYDROCHLORIDE
ANHYDROUS</strong> (UNII: 3I3T11UD2S) (PAROXETINE -
UNII:41VRH5220H)</td>
<td class="formItem">PAROXETINE</td>
<td class="formItem">30 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE
H)</strong> (UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A
POTATO</strong> (UNII: 5856J3G2A2)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;084</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:60505-0084-1</td>
<td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:60505-0084-9</td>
<td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:60505-0084-2</td>
<td class="formItem">100 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:60505-0084-4</td>
<td class="formItem">1000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem">NDC:60505-0084-5</td>
<td class="formItem">10 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem"></td>
<td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075356</td>
<td class="formItem">09/08/2003</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PAROXETINE</strong><br>
<span class="contentTableReg">paroxetine hydrochloride tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0101</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PAROXETINE HYDROCHLORIDE
ANHYDROUS</strong> (UNII: 3I3T11UD2S) (PAROXETINE -
UNII:41VRH5220H)</td>
<td class="formItem">PAROXETINE</td>
<td class="formItem">40 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE
H)</strong> (UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A
POTATO</strong> (UNII: 5856J3G2A2)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;101</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:60505-0101-1</td>
<td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:60505-0101-9</td>
<td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:60505-0101-2</td>
<td class="formItem">100 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:60505-0101-4</td>
<td class="formItem">1000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem">NDC:60505-0101-5</td>
<td class="formItem">10 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem"></td>
<td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">6</th>
<td class="formItem">NDC:60505-0101-7</td>
<td class="formItem">7000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075356</td>
<td class="formItem">09/08/2003</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Apotex Corp. (845263701)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Registrant -</span> Apotex Inc. (209429182)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Apotex Inc.</td>
<td class="formItem"></td>
<td class="formItem">205576023</td>
<td class="formItem">manufacture(60505-0097, 60505-0083,
60505-0084, 60505-0101) , analysis(60505-0097, 60505-0083,
60505-0084, 60505-0101)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="#boxedwarning" target="_blank">Boxed Warnings</a>,
<a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22PAROXETINE%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=PAROXETINE"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=PAROXETINE"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00364&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">PAROXETINE- paroxetine hydrochloride
anhydrous tablet, film coated<br></h3>
<h4>Number of versions: 11</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Feb 9, 2015</td>
<td>11 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=165251">download</a></td>
</tr>
<tr>
<td>Sep 11, 2014</td>
<td>10</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=150761">download</a></td>
</tr>
<tr>
<td>Sep 8, 2014</td>
<td>9</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=150446">download</a></td>
</tr>
<tr>
<td>Feb 18, 2014</td>
<td>8</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=131527">download</a></td>
</tr>
<tr>
<td>Mar 22, 2013</td>
<td>7</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=103373">download</a></td>
</tr>
<tr>
<td>Feb 17, 2012</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=73513">download</a></td>
</tr>
<tr>
<td>Oct 3, 2011</td>
<td>5</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=64311">download</a></td>
</tr>
<tr>
<td>Jul 5, 2011</td>
<td>4</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=58164">download</a></td>
</tr>
<tr>
<td>Jun 8, 2011</td>
<td>3</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=56011">download</a></td>
</tr>
<tr>
<td>Aug 30, 2007</td>
<td>2</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=5382">download</a></td>
</tr>
<tr>
<td>Jun 7, 2007</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=4597">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">PAROXETINE- paroxetine hydrochloride
anhydrous tablet, film coated<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738483">1738483</a></td>
<td>PARoxetine HCl 10 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738483">1738483</a></td>
<td>Paroxetine Hydrochloride 10 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738495">1738495</a></td>
<td>PARoxetine HCl 20 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738495">1738495</a></td>
<td>Paroxetine Hydrochloride 20 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738503">1738503</a></td>
<td>PARoxetine HCl 30 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738503">1738503</a></td>
<td>Paroxetine Hydrochloride 30 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738511">1738511</a></td>
<td>PARoxetine HCl 40 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1738511">1738511</a></td>
<td>Paroxetine Hydrochloride 40 MG Oral Tablet</td>
<td>SCD</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">PAROXETINE- paroxetine hydrochloride
anhydrous tablet, film coated<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=08320ea3-8f93-6f04-5d1c-f69af3eb5a81</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APAROXETINE%2D%20Paroxetine%20Hydrochloride%20Anhydrous%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D08320ea3%2D8f93%2D6f04%2D5d1c%2Df69af3eb5a81%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "PAROXETINE- paroxetine hydrochloride anhydrous tablet, film coated <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
